BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 1139] [Cited by in F6Publishing: 1169] [Article Influence: 162.7] [Reference Citation Analysis]
Number Citing Articles
1 Zarodnyuk IV, Eligulashvili RR, Veselov VV, Mikhalchenko VA, Nanaeva BA, Vardanyan AV, Peda ES. Magnetic resonance enterocolonography for assessing inflammation activity in Crohn’s disease using the CDMI and MEGS indices. Koloproktologiâ 2022;21:39-48. [DOI: 10.33878/10.33878/2073-7556-2022-21-4-39-48] [Reference Citation Analysis]
2 Megna BW, Vaughn BP. Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2022. [DOI: 10.1007/s11894-022-00854-5] [Reference Citation Analysis]
3 Zhu F, Wei C, Wu H, Shuai B, Yu T, Gao F, Yuan Y, Zuo D, Liu X, Zhang L, Fan H. Hypoxic mesenchymal stem cell-derived exosomes alleviate ulcerative colitis injury by limiting intestinal epithelial cells reactive oxygen species accumulation and DNA damage through HIF-1α. International Immunopharmacology 2022;113:109426. [DOI: 10.1016/j.intimp.2022.109426] [Reference Citation Analysis]
4 Veyrard P, Roblin X, Pansart C, Mao R, Nancey S, Killian M, Waeckel L, Berger A, Williet N, Bastide L, Barrau M, Tournier Q, Paul S. Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse. Clinical Immunology Communications 2022;2:33-38. [DOI: 10.1016/j.clicom.2022.02.001] [Reference Citation Analysis]
5 Cortesi PA, Fiorino G, Peyrin‐biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL, Danese S. Non‐invasive monitoring and treat‐to‐target approach are cost‐effective in patients with mild–moderate ulcerative colitis. Aliment Pharmacol Ther 2022. [DOI: 10.1111/apt.17261] [Reference Citation Analysis]
6 Alfarone L, Parigi TL, Gabbiadini R, Dal Buono A, Spinelli A, Hassan C, Iacucci M, Repici A, Armuzzi A. Technological advances in inflammatory bowel disease endoscopy and histology. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1058875] [Reference Citation Analysis]
7 Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izac230] [Reference Citation Analysis]
8 Crowley E, Griffiths AM, Jairath V; pIBD CLINICAL TRIALS OUTCOME GROUP. Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization. Gastroenterology 2022;163:1137-44. [PMID: 35850191 DOI: 10.1053/j.gastro.2022.07.006] [Reference Citation Analysis]
9 Leenhardt R, Koulaouzidis A, Histace A, Baatrup G, Beg S, Bourreille A, de Lange T, Eliakim R, Iakovidis D, Dam Jensen M, Keuchel M, Margalit Yehuda R, McNamara D, Mascarenhas M, Spada C, Segui S, Smedsrud P, Toth E, Tontini GE, Klang E, Dray X, Kopylov U. Key research questions for implementation of artificial intelligence in capsule endoscopy. Therap Adv Gastroenterol 2022;15:17562848221132683. [PMID: 36338789 DOI: 10.1177/17562848221132683] [Reference Citation Analysis]
10 Murphy ME, Bhattacharya S, Axelrad JE. Diagnosis and Monitoring of Ulcerative Colitis. Clin Colon Rectal Surg 2022. [DOI: 10.1055/s-0042-1758047] [Reference Citation Analysis]
11 Scott FI, Ehrlich O, Wood D, Viator C, Rains C, DiMartino L, McArdle J, Adams G, Barkoff L, Caudle J, Cheng J, Kinnucan J, Persley K, Sariego J, Shah S, Heller C, Rubin DT. Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. Inflamm Bowel Dis 2022:izac216. [PMID: 36271884 DOI: 10.1093/ibd/izac216] [Reference Citation Analysis]
12 Rath T, Atreya R, Bodenschatz J, Uter W, Geppert CE, Vitali F, Fischer S, Waldner MJ, Colombel JF, Hartmann A, Neurath MF. Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in IBD: the prospective ERIca trial. Gastroenterology 2022:S0016-5085(22)01192-1. [PMID: 36279923 DOI: 10.1053/j.gastro.2022.10.014] [Reference Citation Analysis]
13 Hunter T, Komocsar WJ, Colletti RB, Liu C, Benkov KJ, Dotson JL, Steiner SJ, Zhang N, Crandall W; ImproveCareNow Network. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease. Curr Med Res Opin 2022;:1-19. [PMID: 36263735 DOI: 10.1080/03007995.2022.2135836] [Reference Citation Analysis]
14 Kitahata S, Furukawa S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Yagi S, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Association between socioeconomic status and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMJ Open Gastroenterol 2022;9:e001000. [PMID: 36261231 DOI: 10.1136/bmjgast-2022-001000] [Reference Citation Analysis]
15 Bohra A, Vasudevan A, Kutaiba N, Van Langenberg DR. Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn’s Disease. Diagnostics 2022;12:2533. [DOI: 10.3390/diagnostics12102533] [Reference Citation Analysis]
16 Shapina MV. Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-90-97] [Reference Citation Analysis]
17 Guez I, Focht G, Greer MC, Cytter-kuint R, Pratt L, Castro DA, Turner D, Griffiths AM, Freiman M. Development of a multimodal machine-learning fusion model to non-invasively assess ileal Crohn’s disease endoscopic activity. Computer Methods and Programs in Biomedicine 2022. [DOI: 10.1016/j.cmpb.2022.107207] [Reference Citation Analysis]
18 Pray C, Wong ECL, Aruljothy A, Dulai PS, Marshall JK, Reinisch W, Narula N. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis. Inflamm Bowel Dis 2022:izac210. [PMID: 36179118 DOI: 10.1093/ibd/izac210] [Reference Citation Analysis]
19 Sudhakar P, Wellens J, Verstockt B, Ferrante M, Sabino J, Vermeire S. Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut 2022:gutjnl-2022-328221. [PMID: 36171081 DOI: 10.1136/gutjnl-2022-328221] [Reference Citation Analysis]
20 Fabian O, Bajer L. Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for? World J Gastroenterol 2022; 28(36): 5300-5312 [DOI: 10.3748/wjg.v28.i36.5300] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cassinotti A, Mezzina N, De Silvestri A, Di Paolo D, Lenti MV, Bezzio C, Stradella D, Mauri M, Zadro V, Ricci C, Casini V, Radice E, Massari A, Maconi G, Saibeni S, Caprioli F, Tari R, Fichera M, Cortelezzi CC, Parravicini M, Tinelli C, Testoni PA, Pace F, Segato S, Invernizzi P, Occhipinti P, Manes G, Di Sabatino A, Pastorelli L, Vecchi M, Ardizzone S. Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study. Eur J Gastroenterol Hepatol 2022. [PMID: 36165081 DOI: 10.1097/MEG.0000000000002443] [Reference Citation Analysis]
22 Facciorusso A, Ramai D, Ricciardelli C, Paolillo R, Maida M, Chandan S, Mohan BP, Domislovic V, Sacco R. Prognostic Role of Post-Induction Fecal Calprotectin Levels in Patients with Inflammatory Bowel Disease Treated with Biological Therapies. Biomedicines 2022;10:2305. [DOI: 10.3390/biomedicines10092305] [Reference Citation Analysis]
23 Becher N, Swaminath A, Sultan K. A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. Ther Clin Risk Manag 2022;18:913-27. [PMID: 36106049 DOI: 10.2147/TCRM.S336139] [Reference Citation Analysis]
24 Argmann C, Hou R, Ungaro RC, Irizar H, Al-taie Z, Huang R, Kosoy R, Venkat S, Song W, Di'narzo AF, Losic B, Hao K, Peters L, Comella PH, Wei G, Atreja A, Mahajan M, Iuga A, Desai PT, Branigan P, Stojmirovic A, Perrigoue J, Brodmerkel C, Curran M, Friedman JR, Hart A, Lamousé-smith E, Wehkamp J, Mehandru S, Schadt EE, Sands BE, Dubinsky MC, Colombel J, Kasarskis A, Suárez-fariñas M. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. [DOI: 10.1136/gutjnl-2021-326451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Narula N, Wong ECL, Moayyedi P, Reinisch W, Marshall JK. Pilot study of an elimination diet in adults with mild to moderate Crohn's disease. Eur J Gastroenterol Hepatol 2022. [PMID: 36165053 DOI: 10.1097/MEG.0000000000002438] [Reference Citation Analysis]
26 Al-ani AH, Vaughan R, Christensen B, Bryant RV, Novak KL. Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease. BJR 2022;95. [DOI: 10.1259/bjr.20211174] [Reference Citation Analysis]
27 Grace A, Usman MA, Ochayi MO, Adams MD, Umar HD, Obalum CD, Akunna GG, Meraiyebu AB, Onwuchekwa C. Elucidating the Anti-Oxidant and Anti-Inflammatory Potentials of Triticum aestivum Against Ulcerative Colitis: an In Vivo and In Silico Study. Phytomedicine Plus 2022. [DOI: 10.1016/j.phyplu.2022.100350] [Reference Citation Analysis]
28 Lee YJ, Park JH. Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr 2022;25:396-405. [PMID: 36148291 DOI: 10.5223/pghn.2022.25.5.396] [Reference Citation Analysis]
29 Vaughan R, Murphy E, Nalder M, Gibson RN, Ardalan Z, Boussioutas A, Christensen B. Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac186. [PMID: 36094156 DOI: 10.1093/ibd/izac186] [Reference Citation Analysis]
30 Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L. Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterol J 2022. [PMID: 36029157 DOI: 10.1002/ueg2.12283] [Reference Citation Analysis]
31 Celani LMS, Egito EST, Azevedo ÍM, Oliveira CN, Dourado D, Medeiros AC. Treatment of colitis by oral negatively charged nanostructured curcumin in rats. Acta Cir Bras 2022;37:e370602. [PMID: 35976279 DOI: 10.1590/acb370602] [Reference Citation Analysis]
32 Knyazev OV, Kagramanova AV, Lishchinskaya AA, Babaian AF, Shkurko TV, Nanaeva BA, Li IA. Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-14-96-106] [Reference Citation Analysis]
33 Yang JY, Lund JL, Pate V, Kappelman MD. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflamm Bowel Dis 2022:izac136. [PMID: 35929644 DOI: 10.1093/ibd/izac136] [Reference Citation Analysis]
34 Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
35 Dulai PS, Rai V, Raffals LE, Lukin D, Hudesman D, Kochhar GS, Damas OM, Sauk JS, Levy AN, Sofia MA, Tuskey A, Deepak P, Yarur AJ, Afzali A, Ananthakrishnan AN, Cross RK, Hanauer SB, Siegel CA. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. Am J Gastroenterol 2022;117:1288-1295. [DOI: 10.14309/ajg.0000000000001775] [Reference Citation Analysis]
36 Qin W, Luo H, Yang L, Hu D, Jiang S, Peng D, Hu J, Liu S. Rubia cordifolia L. ameliorates DSS-induced ulcerative colitis in mice through dual inhibition of NLRP3 inflammasome and IL-6/JAK2/STAT3 pathways. Heliyon 2022;8:e10314. [DOI: 10.1016/j.heliyon.2022.e10314] [Reference Citation Analysis]
37 Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, Principi MB, Bezzio C, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocci G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, Fantini MC; IG-IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol 2022;117:1279-87. [PMID: 35467558 DOI: 10.14309/ajg.0000000000001773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Castiglione F, Imperatore N, Testa A, de Sire R, Nardone OM, Ricciolino S, Di Luna I, Patturelli M, Villani GD, Olmo O, Rispo A. Exploring the concept of deep remission in Crohn's disease: correlation between transmural healing and biomarkers. Therap Adv Gastroenterol 2022;15:17562848221110643. [PMID: 35898191 DOI: 10.1177/17562848221110643] [Reference Citation Analysis]
39 Wong ECL, Yusuf A, Pokryszka J, Dulai PS, Colombel JF, Marshall JK, Reinisch W, Narula N. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease. Inflamm Bowel Dis 2022:izac157. [PMID: 35880680 DOI: 10.1093/ibd/izac157] [Reference Citation Analysis]
40 Buhl S, Steenholdt C, Brynskov J, Christensen KR, Dorn-rasmussen M, Thomsen OØ, Bendtzen K, Klausen TW, Dahlerup JF, Thorsgaard N, Jahnsen J, Molazahi A, Pedersen N, Kjeldsen J, Almer S, Dahl EE, Vind I, Cannon AG, Marsal J, Sipponen T, Agnholt JS, Kievit HAL, Aure SL, Martinsen L, Meisner S, Hansen JM, Ainsworth MA. Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease. NEJM Evidence 2022;1. [DOI: 10.1056/evidoa2200061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Choi SY, Kim ES, Jeon TY, Lee YM, Lee SM, Choe B, Choe YH, Kang B. Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics. Aliment Pharmacol Ther. [DOI: 10.1111/apt.17161] [Reference Citation Analysis]
42 Ferrante M, Irving PM, Selinger CP, D'Haens G, Kuehbacher T, Seidler U, Gropper S, Haeufel T, Forgia S, Danese S, Klaus J, Feagan BG; spesolimab in UC phase II clinical trial investigators. Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opin Drug Saf 2022. [PMID: 35861588 DOI: 10.1080/14740338.2022.2103536] [Reference Citation Analysis]
43 Meyer A, Fumery M, Peyrin-Biroulet L, Filippi J, Altwegg R, Bouhnik Y, Serrero M, Laharie D, Roblin X, Nachury M, Abitbol V, Cadiot G, Nancey S, Allez M, Gilletta C, Vuitton L, Savoye G, Nahon S, Bourrier A, Buisson A, Bouguen G, Bourreille A, Viennot S, Carbonnel F, Amiot A. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol 2022;:1-9. [PMID: 35819361 DOI: 10.1080/00365521.2022.2095668] [Reference Citation Analysis]
44 Stojkovic Lalosevic M, Sokic Milutinovic A, Matovic Zaric V, Lolic I, Toplicanin A, Dragasevic S, Stojkovic M, Stojanovic M, Aleksic M, Stjepanovic M, Martinov Nestorov J, Popovic DD, Glisic T, Sainaghi PP. Intestinal Ultrasonography as a Tool for Monitoring Disease Activity in Patients with Ulcerative Colitis. International Journal of Clinical Practice 2022;2022:1-6. [DOI: 10.1155/2022/3339866] [Reference Citation Analysis]
45 Fiorino G, Danese S, Peyrin-Biroulet L, Sans M, Bonelli F, Calleri M, Zierold C, Pollastro R, Moretti F, Malesci A. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. United European Gastroenterol J 2022. [PMID: 35789124 DOI: 10.1002/ueg2.12268] [Reference Citation Analysis]
46 Header D, Aboelwafa R, Elkeleny M, Bedewy E, Ellakany A. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2022.06.007] [Reference Citation Analysis]
47 Vaughan R, Tjandra D, Patwardhan A, Mingos N, Gibson R, Boussioutas A, Ardalan Z, Al-Ani A, Gibson PR, Christensen B. Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2022;56:84-94. [PMID: 35343603 DOI: 10.1111/apt.16892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Abdelhamid AM, Youssef ME, Cavalu S, Mostafa-Hedeab G, Youssef A, Elazab ST, Ibrahim S, Allam S, Elgharabawy RM, El-Ahwany E, Amin NA, Shata A, Mohammed OA, Ibrahim Abdeldaiem MS, Alhowail A, El-Saber Batiha G, El-Mahmoudy EA, Attia M, Allam A, Zaater MY, Osman MM, Nader M, Taha A, Makarem NA, Saber S. Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. Front Pharmacol 2022;13:887233. [PMID: 35754464 DOI: 10.3389/fphar.2022.887233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Reinisch W, Serone A, Hébuterne X, Kühbacher T, Kłopocka M, Roblin X, Brodbeck J, Etchevers K, Galien R, Grant E, Tasset C, Yoon OK, Zaboli S, Vermeire S. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. Tissue Barriers 2022;:2088961. [PMID: 35762272 DOI: 10.1080/21688370.2022.2088961] [Reference Citation Analysis]
50 Liu N, Wang H, Yang Z, Zhao K, Li S, He N. The role of functional oligosaccharides as prebiotics in ulcerative colitis. Food Funct 2022. [PMID: 35703137 DOI: 10.1039/d2fo00546h] [Reference Citation Analysis]
51 Gonzalez-vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-clotet A, López-garcía A, Murciano Gonzalo F, Abril Rodriguez L, de Jesús-gil C, Ruiz-romeu E, Sans-de San Nicolàs L, Santamaria-babí LF, Márquez-mosquera L. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. Front Med 2022;9:837294. [DOI: 10.3389/fmed.2022.837294] [Reference Citation Analysis]
52 Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis 2022:izac117. [PMID: 35704691 DOI: 10.1093/ibd/izac117] [Reference Citation Analysis]
53 Jongsma MME, Vuijk SA, Cozijnsen MA, van Pieterson M, Norbruis OF, Groeneweg M, Wolters VM, van Wering HM, Hojsak I, Kolho K, van Wijk MP, Teklenburg-roord STA, de Meij TGJ, Escher JC, de Ridder L. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease. Eur J Pediatr. [DOI: 10.1007/s00431-022-04496-7] [Reference Citation Analysis]
54 Minnis-lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol 2022;13:e44-50. [DOI: 10.1136/flgastro-2022-102187] [Reference Citation Analysis]
55 Wilkens R, Liao D, Gregersen H, Glerup H, Peters DA, Buchard C, Tøttrup A, Krogh K. Biomechanical Properties of Strictures in Crohn’s Disease: Can Dynamic Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography Predict Stiffness? Diagnostics 2022;12:1370. [DOI: 10.3390/diagnostics12061370] [Reference Citation Analysis]
56 Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai PS. Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut 2022;71:1078-87. [PMID: 33766910 DOI: 10.1136/gutjnl-2020-323799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
57 Smith RL, Taylor KM, Friedman AB, Gibson DJ, Con D, Gibson PR. Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2022;34:613-21. [PMID: 35352696 DOI: 10.1097/MEG.0000000000002367] [Reference Citation Analysis]
58 Lei N, Kong P, Chen S, Wang Q, Tang X, Liu F. Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor-κappaB signaling. Eur J Gastroenterol Hepatol 2022;34:630-9. [PMID: 35412486 DOI: 10.1097/MEG.0000000000002370] [Reference Citation Analysis]
59 Gana JC, Sepúlveda A, Orlanski-meyer E, Villarroel del Pino LA, de la Piedra Bustamante MJ, Olivares Labbe MT; Cochrane Gut Group. Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn’s disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014497] [Reference Citation Analysis]
60 Janker L, Schuster D, Bortel P, Hagn G, Brunmair J, Meier-menches SM, Mader JC, Slany A, Bileck A, Madl C, Unger L, Hennlich B, Weitmayr B, Del Favero G, Pils D, Pukrop T, Pfisterer N, Feichtenschlager T, Gerner C. Multi-omics empowered deep phenotyping of ulcerative colitis.. [DOI: 10.1101/2022.05.25.22275502] [Reference Citation Analysis]
61 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
62 Nardone OM, Calabrese G, Testa A, Caiazzo A, Fierro G, Rispo A, Castiglione F. The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. Front Med 2022;9:898092. [DOI: 10.3389/fmed.2022.898092] [Reference Citation Analysis]
63 Freitas M, de Castro FD, Macedo Silva V, Arieira C, Cúrdia Gonçalves T, Leite S, Moreira MJ, Cotter J. Ultrasonographic scores for ileal Crohn's disease assessment: Better, worse or the same as contrast-enhanced ultrasound? BMC Gastroenterol 2022;22:252. [PMID: 35585503 DOI: 10.1186/s12876-022-02326-6] [Reference Citation Analysis]
64 Tang W, Hu W, Shi P, Ye Z, Wu J, Zhang Y, Wang Y, Huang Y. The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn’s Disease Patients. Front Pediatr 2022;10:874425. [DOI: 10.3389/fped.2022.874425] [Reference Citation Analysis]
65 Venkatapurapu SP, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R, Kumar K, Sato Y, Behar M, Offner P, Dwivedi G, Miyasaka H, Suzuki RK, Hamada AL, D'Alessandro PM, Fernandez J. A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther 2022. [PMID: 35581423 DOI: 10.1007/s12325-022-02144-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hwang J, Moon S, Lee YJ, Park JH, Kim Y, Kim TU, Ryu H. Capsule Endoscopy versus Magnetic Resonance Enterography for Evaluation of Pediatric Small Bowel Crohn’s Disease: Prospective Study. JCM 2022;11:2760. [DOI: 10.3390/jcm11102760] [Reference Citation Analysis]
67 Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines 2022;10:759. [DOI: 10.3390/vaccines10050759] [Reference Citation Analysis]
68 Oddsson SJ, Gunnarsdottir T, Johannsdottir LG, Amundadottir ML, Frimannsdottir A, Molander P, Ylanne AK, Islind AS, Oskarsdottir M, Thorgeirsson T. A new Digital Therapeutic Intervention for Patients with Inflammatory Bowel Disease: Program Evaluation (Preprint).. [DOI: 10.2196/preprints.39331] [Reference Citation Analysis]
69 Taxonera C, Fernández-Aceñero MJ, Olivares D, Calvo M, Casis B, Bermejo F, López Serrano P, Iborra M, Mesonero F, Boscá Watts M, Díaz Del Arco C, Vera I, Olivares S, Algaba A, Alba C. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35509152 DOI: 10.1111/apt.16964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Header D, Aboelwafa R, Elkeleny M, Bedewy E, Ellakany A. El índice proteína C reactiva/albúmina como marcador para detectar colitis aguda ulcerosa grave en pacientes egipcios. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.03.010] [Reference Citation Analysis]
71 Xu S, Yang Q, Wang R, Tian C, Ji Y, Tan H, Zhao P, Kaplan DL, Wang F, Xia Q. Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitis. Acta Biomater 2022;144:81-95. [PMID: 35288310 DOI: 10.1016/j.actbio.2022.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Nardone OM, Snir Y, Hodson J, Cannatelli R, Labarile N, Siau K, Hassan C, Yanai H, Dotan I, Ghosh S, Iacucci M. Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:175628482210925. [DOI: 10.1177/17562848221092594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
74 Villablanca EJ, Selin K, Hedin CRH. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat Rev Gastroenterol Hepatol 2022. [PMID: 35440774 DOI: 10.1038/s41575-022-00604-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
75 Marion L, Amélie B, Zoubir D, Guillaume C, Elise M, Hedia B, Margaux LS, Aude M, Camille B. Histological Indices and Risk of Recurrence in Crohn’s Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izac074] [Reference Citation Analysis]
76 Ha C, Mcgovern D, Melmed GY. Crohn's disease: clinical manifestations and management. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch64] [Reference Citation Analysis]
77 Singh S, Dulai PS. Ulcerative colitis: clinical manifestations and management. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch63] [Reference Citation Analysis]
78 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
79 Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2022:izac075. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
80 Agrawal M, Petralia F, Tepler A, Durbin L, Reinisch W, Colombel JF, Shah SC. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflamm Bowel Dis 2022:izac067. [PMID: 35366313 DOI: 10.1093/ibd/izac067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hunter T, Komocsar WJ, Liu C, Colletti RB, Steiner SJ, Dotson JL, Benkov K, Zhang N, Crandall W. Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac009] [Reference Citation Analysis]
82 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022;162:1476-92. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
83 Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, Shan M, Travis S. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes 2022;6:31. [PMID: 35362902 DOI: 10.1186/s41687-022-00439-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022;162:1424-38. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
85 Keefer L, Bedell A, Norton C, Hart AL. How Should Pain, Fatigue, and Emotional Wellness Be Incorporated Into Treatment Goals for Optimal Management of Inflammatory Bowel Disease? Gastroenterology 2022;162:1439-51. [PMID: 34995528 DOI: 10.1053/j.gastro.2021.08.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
86 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
87 Giri S, Sundaram S. Low Dose Azathioprine with Allopurinol in IBD: Early Days to Call It a Recipe for Success. Dig Dis Sci 2022. [PMID: 35244826 DOI: 10.1007/s10620-021-07375-7] [Reference Citation Analysis]
88 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
89 Marín-jiménez I, Acosta MB, Esteve M, Castro-laria L, García-lópez S, Ceballos D, Echarri A, Martín-arranz MD, Busquets D, Llaó J, Navarro-llavat M, Huguet JM, Argüelles-arias F, Vicente R, Boudet JM, Díaz G, Sánchez-migallón AM, Casellas F. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. Gastroenterología y Hepatología (English Edition) 2022;45:165-176. [DOI: 10.1016/j.gastre.2021.04.007] [Reference Citation Analysis]
90 Franco FCZ, Oliveira MCCD, Gaburri PD, Franco DCZ, Chebli JMF. HIGH PREVALENCE OF NON-ADHERENCE TO ULCERATIVE COLITIS THERAPY IN REMISSION: KNOWING THE PROBLEM TO PREVENT LOSS. Arq Gastroenterol 2022;59:40-6. [DOI: 10.1590/s0004-2803.202200001-08] [Reference Citation Analysis]
91 Allocca M, Dell'Avalle C, Craviotto V, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterol J 2022. [PMID: 35233934 DOI: 10.1002/ueg2.12206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Park SB, Kim S, Lee J, Lee YJ, Baek DH, Seo GS, Kim ES, Kim S, Kim SY. Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02178-0] [Reference Citation Analysis]
93 Chamorro-de-vega E, Romero-jimenez RM, Escudero-vilaplana VD, Ais-larisgoitia A, Lobato-matilla E, González-fernández CM, Menchén L, Baniandrés-rodríguez O, Ibares-frias L, Lobo-rodríguez C, Herranz A, Sanjurjo M. Information and communication technologies in Patients with Immune-Mediated Inflammatory Diseases: Cross-Sectional Survey (Preprint). Journal of Medical Internet Research. [DOI: 10.2196/37445] [Reference Citation Analysis]
94 Chamorro-de-vega E, Romero-jimenez RM, Escudero-vilaplana VD, Ais-larisgoitia A, Lobato-matilla E, González-fernández CM, Menchén L, Baniandrés-rodríguez O, Ibares-frias L, Lobo-rodríguez C, Herranz A, Sanjurjo M. Use of mHealth by Patients with Immune-Mediated Inflammatory Diseases: Cross-Sectional Survey (Preprint).. [DOI: 10.2196/preprints.37445] [Reference Citation Analysis]
95 Monmousseau F, Mulot L, Rusch E, Picon L, Laharie D, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-poisson C, Dib N, Des Garets V, Brunet-houdard S, Aubourg A; on behalf of the COQC-PIT Study Group. Predictors of each quality of life dimension in Crohn’s disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2021.2025419] [Reference Citation Analysis]
96 Mas EB, Calvo XC. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients. JCM 2022;11:1076. [DOI: 10.3390/jcm11041076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Sutton RT, Zai Ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Sci Rep 2022;12:2748. [PMID: 35177717 DOI: 10.1038/s41598-022-06726-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
98 Vespa E, D’amico F, Sollai M, Allocca M, Furfaro F, Zilli A, Dal Buono A, Gabbiadini R, Danese S, Fiorino G. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. JCM 2022;11:939. [DOI: 10.3390/jcm11040939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Danese S, Vermeire S, D'haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-biroulet L. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00474-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
100 Serafini MA, Paz AH, Nunes NS. Cholinergic immunomodulation in inflammatory bowel diseases. Brain, Behavior, & Immunity - Health 2022;19:100401. [DOI: 10.1016/j.bbih.2021.100401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022;162:495-508. [PMID: 34748774 DOI: 10.1053/j.gastro.2021.10.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
102 Dulai PS, Rai V, Raffals LE, Lukin D, Hudesman D, Kochhar GS, Damas OM, Sauk JS, Levy AN, Sofia MA, Tuskey A, Deepak P, Yarur AJ, Afzali A, Ananthakrishnan AN, Cross RK, Hanauer SB, Siegel CA. Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis.. [DOI: 10.1101/2022.01.24.22269684] [Reference Citation Analysis]
103 Zanger K, Nimkin K, Israel EJ, Shih AR. Case 3-2022: A 14-Year-Old Boy with Fever, Joint Pain, and Abdominal Cramping. N Engl J Med 2022;386:375-83. [PMID: 35081284 DOI: 10.1056/NEJMcpc2115850] [Reference Citation Analysis]
104 Oh K, Oh EH, Noh SM, Park SH, Kim N, Hwang SW, Park SH, Yang D, Byeon J, Myung S, Yang S, Ye BD. Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy. Clin Transl Gastroenterol 2022;Publish Ahead of Print. [DOI: 10.14309/ctg.0000000000000442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Parfenov AI, Knyazev OV, Babayan AF, Kagramanova AV. Low adherence to treatment is a weak link in the problems of ulcerative colitis. Terapevticheskii arkhiv 2022;93:1419-27. [DOI: 10.26442/00403660.2021.12.201172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Knyazev OV, Khomeriki SG, Kagramanova АV, Lishchinskaya AA, Smirnova OA, Noskova KK, Parfenov AI. Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. Terapevticheskii arkhiv 2022;93:1435-42. [DOI: 10.26442/00403660.2021.12.201212] [Reference Citation Analysis]
107 Radford SJ, Taylor S, Moran G. Ultrasound use to assess Crohn’s disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
109 Wang J, Wang X, Ma X, Xu B, Chen L, Chen C, Liu W, Liu Y, Xiang Z. Therapeutic effect of Patrinia villosa on TNBS-induced ulcerative colitis via metabolism, vitamin D receptor and NF-κB signaling pathways. J Ethnopharmacol 2022;:114989. [PMID: 35032589 DOI: 10.1016/j.jep.2022.114989] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Jeong TJ, Kim ES, Kwon Y, Kim S, Seo SW, Choe YH, Kim MJ. Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission. Sci Rep 2022;12:507. [PMID: 35017546 DOI: 10.1038/s41598-021-04304-6] [Reference Citation Analysis]
111 Değirmenci Saltürk AG. İnflamatuvar Barsak Hastalarında Vedolizumab Deneyimi: Tek Merkez Verileri. Akademik Gastroenteroloji Dergisi 2022. [DOI: 10.17941/agd.1005038] [Reference Citation Analysis]
112 Park J, Kang SJ, Yoon H, Park J, Oh HJ, Na HY, Lee HS, Shin CM, Park YS, Kim N, Lee DH. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse. Inflamm Bowel Dis 2022:izab340. [PMID: 35016209 DOI: 10.1093/ibd/izab340] [Reference Citation Analysis]
113 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
114 Kwapisz L, Bruining DH, Fletcher JG. Using MR Enterography and CT Enterography for Routine Crohn's Surveillance: How We Do It Now, and How We Hope to Do it in the Future. Korean J Radiol 2022;23:1-5. [PMID: 34983088 DOI: 10.3348/kjr.2021.0846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Wu S, Zeng L, Li W, Wu YT, Jing JG, Zhuang H, Wang YF. The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease. Dig Liver Dis 2022:S1590-8658(21)00896-3. [PMID: 34991975 DOI: 10.1016/j.dld.2021.12.009] [Reference Citation Analysis]
117 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Calavrezos L, Bannas P, Warncke M, Wiegard C, Huber S, Manthey C. Transabdominal Ultrasound and Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Observational Retrospective Single-Center Study. Ultrasound Int Open 2022;8:E22-8. [PMID: 36172490 DOI: 10.1055/a-1781-4410] [Reference Citation Analysis]
119 Tetangco EP, Stein AC. Medical Treatment of Intestinal Crohn's disease. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100862] [Reference Citation Analysis]
120 D'Arcangelo G, Abi Nader E, Charbit-Henrion F, Talbotec C, Goulet O, Ruemmele FM, Pigneur B. Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study. J Pediatr Gastroenterol Nutr 2022;74:79-84. [PMID: 34962501 DOI: 10.1097/MPG.0000000000003301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable bowel syndrome in inflammatory bowel disease. Synergy in alterations of the gut-brain axis? Gastroenterología y Hepatología (English Edition) 2022;45:66-76. [DOI: 10.1016/j.gastre.2021.02.007] [Reference Citation Analysis]
122 Graff LA, Lackner JM. Gastrointestinal Disorders: Inflammatory Bowel Disease and Irritable Bowel Syndrome. Comprehensive Clinical Psychology 2022. [DOI: 10.1016/b978-0-12-818697-8.00118-7] [Reference Citation Analysis]
123 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_29] [Reference Citation Analysis]
125 Yamada K, Ishikawa T, Kawashima H, Ohno E, Iida T, Ishikawa E, Mizutani Y, Sawada T, Maeda K, Yamamura T, Kakushima N, Furukawa K, Nakamura M, Ishigami M, Fujishiro M. Evaluation of ulcerative colitis activity using transabdominal ultrasound shear wave elastography. Quant Imaging Med Surg 2022;12:618-26. [PMID: 34993106 DOI: 10.21037/qims-21-403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Aloi M, Cucchiara S. Crohn’s Disease. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_28] [Reference Citation Analysis]
127 Bhattacharya S, Cross RK. Medical treatment of ulcerative colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100863] [Reference Citation Analysis]
128 Smith RK, Holubar SD. Medical Therapy for Crohn’s Disease. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_46] [Reference Citation Analysis]
129 Ye BD. Indication of Small Bowel Evaluation in Crohn’s Disease. Small Intestine Disease 2022. [DOI: 10.1007/978-981-16-7239-2_38] [Reference Citation Analysis]
130 Pai RK, Lauwers GY, Pai RK. Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. Adv Anat Pathol 2022;29:37-47. [PMID: 34879037 DOI: 10.1097/PAP.0000000000000326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Kim JE, Won H, Kim YH, Kim ER, Hong SN, Chang DK. Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naïve patients with Crohn's disease. Scand J Gastroenterol 2021;:1-3. [PMID: 34967701 DOI: 10.1080/00365521.2021.2020332] [Reference Citation Analysis]
132 Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs 2021. [PMID: 34951696 DOI: 10.1007/s40259-021-00512-8] [Reference Citation Analysis]
133 Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34932423 DOI: 10.1080/00365521.2021.2015801] [Reference Citation Analysis]
134 Geldof J, LeBlanc JF, Lucaciu L, Segal J, Lees CW, Hart A. Are we addressing the top 10 research priorities in IBD? Frontline Gastroenterol 2021;12:564-9. [PMID: 34917313 DOI: 10.1136/flgastro-2020-101579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Oba J, Sobrado CW, Damião AOMC, Azevedo M, Carlos A, Queiroz N, Len CA, Toma RK, Deboni M, Ozaki MJ, Carrilho FJ, Nahas S, Silva CA. HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH REDUCTION IN SCHOOL AND WORK PRODUCTIVITY RATHER THAN PHYSICAL IMPAIRMENT: A MULTIDISCIPLINARY STUDY. Arq Gastroenterol 2021;58:541-7. [PMID: 34909863 DOI: 10.1590/S0004-2803.202100000-96] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Belousova EA, Kozlov IG, Abdulganieva DI, Alexeeva OP, Gubonina IV, Lishchinskaya AA, Tarasova LV, Chashkova EY, Shapina MV, Shifrin OS, Shchukina OB. Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021). Alʹm klin med 2021;49:485-495. [DOI: 10.18786/2072-0505-2021-49-060] [Reference Citation Analysis]
137 Magro F, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, Danese S, Peyrin-Biroulet L, Estevinho MM, Moreira P; on behalf GEDII (Portuguese IBD Group). Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis. United European Gastroenterol J 2021. [PMID: 34907660 DOI: 10.1002/ueg2.12183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Aniwan S, Loftus EV. The Natural History of Inflammatory Bowel Disease. Curr Treat Options Gastro 2021;19:597-607. [DOI: 10.1007/s11938-021-00363-w] [Reference Citation Analysis]
140 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
141 Na SY, Lim YJ. Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom? Diagnostics (Basel) 2021;11:2240. [PMID: 34943477 DOI: 10.3390/diagnostics11122240] [Reference Citation Analysis]
142 Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals (Basel) 2021;14:1230. [PMID: 34959633 DOI: 10.3390/ph14121230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
145 Mitselos IV, Fousekis FS, Lamouri C, Katsanos KH, Christodoulou DK. Current noninvasive modalities in Crohn's disease monitoring. Ann Gastroenterol 2021;34:770-80. [PMID: 34815642 DOI: 10.20524/aog.2021.0648] [Reference Citation Analysis]
146 Fritz B. Gastrointestinale Erkrankungen: Forschungsschwerpunkte der Pharmafirmen. Drug Res (Stuttg) 2021;71:S5-6. [PMID: 34788875 DOI: 10.1055/a-1606-5387] [Reference Citation Analysis]
147 Chun J. Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis. Gut Liver 2021;15:793-4. [PMID: 34782487 DOI: 10.5009/gnl210512] [Reference Citation Analysis]
148 Jia J, Zhang P, Zhang C, Jiang G, Zheng W, Song S, Ai C. Sulfated polysaccharides from pacific abalone attenuated DSS-induced acute and chronic ulcerative colitis in mice via regulating intestinal micro-ecology and the NF-κB pathway. Food Funct 2021;12:11351-65. [PMID: 34668909 DOI: 10.1039/d1fo02431k] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
149 Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2021. [PMID: 34783066 DOI: 10.1111/apt.16700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
150 Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. Scand J Gastroenterol 2021;:1-8. [PMID: 34779308 DOI: 10.1080/00365521.2021.2002397] [Reference Citation Analysis]
151 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
152 Bouhuys M, Lexmond WS, Dijkstra G, Lobatón T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open 2021;11:e054154. [PMID: 34732500 DOI: 10.1136/bmjopen-2021-054154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Vaughn BP. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. J Clin Med 2021;10:4990. [PMID: 34768509 DOI: 10.3390/jcm10214990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis 2021:jjab183. [PMID: 34664635 DOI: 10.1093/ecco-jcc/jjab183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Adler J, Eder SJ, Gebremariam A, French KR, Moncion I, Singer AAM, Bass LM, Moran CJ, Picoraro JA, Moses J, Lewis JD, Sandberg KC, Mar SJ, Ebach DR, Saeed SA, Rosh JR, Neef HC, Kaplan JL, Goyal A, Del Rosario JF, Zacur GM. Development and Testing of a New Simplified Endoscopic Mucosal Assessment for Crohn's Disease: The SEMA-CD. Inflamm Bowel Dis 2021;27:1585-92. [PMID: 33382069 DOI: 10.1093/ibd/izaa307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
156 Yao JY, Zhang M, Wang W, Peng X, Zhao JZ, Liu T, Li ZW, Sun HT, Hu P, Zhi M. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study. BMC Gastroenterol 2021;21:380. [PMID: 34663208 DOI: 10.1186/s12876-021-01946-8] [Reference Citation Analysis]
157 Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel Dis 2021;27:1674-83. [PMID: 33295611 DOI: 10.1093/ibd/izaa318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Goodsall TM, Nguyen TM, Parker CE, Ma C, Andrews JM, Jairath V, Bryant RV. Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. J Crohns Colitis 2021;15:125-42. [PMID: 32614386 DOI: 10.1093/ecco-jcc/jjaa129] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
159 Bots S, De Voogd F, De Jong M, Ligtvoet V, Löwenberg M, Duijvestein M, Ponsioen CY, D'Haens G, Gecse KB. Point-of-care intestinal ultrasound in IBD patients: disease management and diagnostic yield in a real-world cohort and proposal of a point-of-care algorithm. J Crohns Colitis 2021:jjab175. [PMID: 34636839 DOI: 10.1093/ecco-jcc/jjab175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
160 Zhao ML, Chen T, Zhang TH, Tian F, Wan X. H19 Overexpression Improved Efficacy of Mesenchymal Stem Cells in Ulcerative Colitis by Modulating the miR-141/ICAM-1 and miR-139/CXCR4 Axes. Dis Markers 2021;2021:7107705. [PMID: 34630738 DOI: 10.1155/2021/7107705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
162 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. J Crohns Colitis 2021;15:1649-57. [PMID: 33693522 DOI: 10.1093/ecco-jcc/jjab045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
164 Tiankanon K, Limsrivilai J, Poocharoenwanich N, Phaophu P, Subdee N, Kongtub N, Aniwan S. Burden of Inflammatory Bowel Disease on Patient Mood, Fatigue, Work, and Health-Related Quality of Life in Thailand: A Case-Control Study. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab077] [Reference Citation Analysis]
165 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology 2021;161:1156-1167.e3. [PMID: 34144047 DOI: 10.1053/j.gastro.2021.06.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
166 Gagnon A, Beauchesne W, Tessier L, David C, Berbiche D, Lavoie A, Michaud-herbst A, Tremblay K. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab049] [Reference Citation Analysis]
167 Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit 2021;43:645-51. [PMID: 33346627 DOI: 10.1097/FTD.0000000000000849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Ostanek B, Drobne D, Grabnar I. Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 2021;13:1587. [PMID: 34683880 DOI: 10.3390/pharmaceutics13101587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Ricci L, Toussaint Y, Becker J, Najjar H, Renier A, Choukour M, Buisson A, Devos C, Epstein J, Peyrin Biroulet L, Guillemin F. Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00774-X. [PMID: 34588153 DOI: 10.1016/j.dld.2021.09.005] [Reference Citation Analysis]
171 Zhang L, Wu YB, Dai YK, Liu Q, Ren YJ, Xu SJ, Pan HG, Chen WJ, Li RL, Hu L. Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. PLoS One 2021;16:e0257599. [PMID: 34543327 DOI: 10.1371/journal.pone.0257599] [Reference Citation Analysis]
172 Soriano CR, Powell CR, Chiorean MV, Simianu VV. Role of hospitalization for inflammatory bowel disease in the post-biologic era. World J Clin Cases 2021; 9(26): 7632-7642 [PMID: 34621815 DOI: 10.12998/wjcc.v9.i26.7632] [Reference Citation Analysis]
173 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
174 Truyens M, De Ruyck E, Gonzales GB, Bos S, Laukens D, De Vos M. Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals. J Clin Med 2021;10:4107. [PMID: 34575218 DOI: 10.3390/jcm10184107] [Reference Citation Analysis]
175 Gatti S, Del Baldo G, Catassi G, Faragalli A, Aloi M, Bramuzzo M, D'Arcangelo G, Felici E, Fuoti M, Lega S, Panceri R, Pastore M, Penagini F, Gesuita R, Catassi C. Factors associated with quality of life in Italian children and adolescents with IBD. Sci Rep 2021;11:18076. [PMID: 34508152 DOI: 10.1038/s41598-021-97661-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Zhou T, Sheng Y, Guan H, Meng R, Wang Z. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Front Public Health 2021;9:704889. [PMID: 34490187 DOI: 10.3389/fpubh.2021.704889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Lundquist LR, Rasmussen B, Waldorff FB, Wehberg S, Kjeldsen J, Haastrup P. Predictors of health-related quality of life in patients with Crohn's disease receiving biological therapy. Scand J Gastroenterol 2021;:1-8. [PMID: 34493132 DOI: 10.1080/00365521.2021.1974086] [Reference Citation Analysis]
178 Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, Danese S, Villanacci V, Feakins R. ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. J Crohns Colitis 2020;14:1503-11. [PMID: 32504534 DOI: 10.1093/ecco-jcc/jjaa110] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 49.0] [Reference Citation Analysis]
179 Guez I, Focht G, Greer MC, Cytter-kuint R, Pratt L, Castro DA, Turner D, Griffiths AM, Freiman M. Magnetic Resonance Enterography indices for ileal Crohn’s disease assessment: Comparison between classical and machine-learning-based indices.. [DOI: 10.1101/2021.08.29.21262424] [Reference Citation Analysis]
180 Skamnelos A, Lazaridis N, Vlachou E, Koukias N, Apostolopoulos P, Murino A, Christodoulou D, Despott EJ. The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021. Ann Gastroenterol 2021;34:599-611. [PMID: 34475730 DOI: 10.20524/aog.2021.0652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Taylor J. Patient access to biological medications for ulcerative colitis. Gastrointestinal Nursing 2021;19:32-39. [DOI: 10.12968/gasn.2021.19.7.32] [Reference Citation Analysis]
182 Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A. Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1524-34. [PMID: 32533769 DOI: 10.1093/ecco-jcc/jjaa098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
183 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
184 Sparrow MP. Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lémann Index? Gastroenterology 2021;161:800-2. [PMID: 34175282 DOI: 10.1053/j.gastro.2021.06.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Defendenti C, Tarkowski M, Borille S, Cassinotti A, Massari A, Birindelli S, Riva A, Ardizzone S, Panteghini M. Anti-tumour necrosis factor α antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. Int Immunopharmacol 2021;100:108081. [PMID: 34461492 DOI: 10.1016/j.intimp.2021.108081] [Reference Citation Analysis]
186 Salvatore S. Eosinophilic esophagitis: When pathologists make the difference. J Pediatr (Rio J) 2021:S0021-7557(21)00113-3. [PMID: 34478687 DOI: 10.1016/j.jped.2021.08.001] [Reference Citation Analysis]
187 Bikbavova GR, Livzan MA, Novikov DG, Bambulskaya EA. Precision medicine and inflammatory bowel diseases: concept, strategies, future. jour 2021;1:121-129. [DOI: 10.31146/1682-8658-ecg-190-6-121-129] [Reference Citation Analysis]
188 Liu S, Eisenstein S. State-of-the-art surgery for ulcerative colitis. Langenbecks Arch Surg 2021;406:1751-61. [PMID: 34453611 DOI: 10.1007/s00423-021-02295-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Lo B, Burisch J. Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. Artif Intell Gastrointest Endosc 2021; 2(4): 95-102 [DOI: 10.37126/aige.v2.i4.95] [Reference Citation Analysis]
190 Podolskaya DV, Shapina MV, Baranova TA, Tishaeva IA, Alexandrov TL, Knyazev OV, Nanaeva BA. Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. Koloproktologiâ 2021;20:43-50. [DOI: 10.33878/10.33878/2073-7556-2021-20-3-43-50] [Reference Citation Analysis]
191 Podolskaya DV, Shapina MV, Baranova TA, Tishaeva IA, Alexandrov TL, Knyazev OV, Nanaeva BA. Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. Koloproktologiâ 2021;20:43-50. [DOI: 10.33878/2073-7556-2021-20-3-43-50] [Reference Citation Analysis]
192 Karimi N, Kanazaki R, Lukin A, Moore AR, Williams AJ, Connor S. Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician-patient dialogue to inform research and practice. BMJ Open 2021;11:e051053. [PMID: 34452967 DOI: 10.1136/bmjopen-2021-051053] [Reference Citation Analysis]
193 Lopez RN, Day AS. The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1390-1. [PMID: 32767152 DOI: 10.1007/s10620-020-06512-y] [Reference Citation Analysis]
194 Knyazev OV, Kagramanova AV, Khomeriki SG, Parfenov AI. Is histological remission of ulcerative colitis achievable? Terapevticheskii arkhiv 2021;93:975-81. [DOI: 10.26442/00403660.2021.08.200981] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021. [PMID: 34388143 DOI: 10.14309/ajg.0000000000001396] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
196 He N, Wang Y, Zhou Z, Liu N, Jung S, Lee MS, Li S. Preventive and Prebiotic Effect of α-Galacto-Oligosaccharide against Dextran Sodium Sulfate-Induced Colitis and Gut Microbiota Dysbiosis in Mice. J Agric Food Chem 2021;69:9597-607. [PMID: 34378931 DOI: 10.1021/acs.jafc.1c03792] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
197 Rogers CC, Moutinho TJ Jr, Liu X, Valdez RS. Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work. JMIR Hum Factors 2021;8:e27452. [PMID: 34383664 DOI: 10.2196/27452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Zhang B, Gulati A, Alipour O, Shao L. Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis 2020;14:1413-23. [PMID: 32335670 DOI: 10.1093/ecco-jcc/jjaa087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
199 Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol 2021;33:670-9. [PMID: 33741797 DOI: 10.1097/MEG.0000000000002087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
200 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Perez-Jeldres T, Yarur A, Behm B, Dulai PS, Patel D, Bamias G, Rivera-Nieves J. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. J Crohns Colitis 2020;14:1364-77. [PMID: 32239151 DOI: 10.1093/ecco-jcc/jjaa067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
201 Christensen B, Hanauer SB, Gibson PR, Turner JR, Hart J, Rubin DT. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis 2020;14:1345-53. [PMID: 32267926 DOI: 10.1093/ecco-jcc/jjaa068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
202 Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2021;33:346-57. [PMID: 32889976 DOI: 10.1097/MEG.0000000000001917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
203 Ankersen DV, Noack S, Munkholm P, Sparrow MP. E-Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of need. Intern Med J 2021;51:1207-11. [PMID: 34346152 DOI: 10.1111/imj.15132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
205 De Voogd F, Wilkens R, Gecse K, Allocca M, Novak K, Lu C, D'Haens G, Maaser C. A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis. J Crohns Colitis 2021;15:1284-90. [PMID: 33420784 DOI: 10.1093/ecco-jcc/jjaa267] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 23.0] [Reference Citation Analysis]
206 Wu Y, Yang X, Li G, Liu X. Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking. Phytomedicine Plus 2021;1:100081. [DOI: 10.1016/j.phyplu.2021.100081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
207 Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol 2021;116:1709-19. [PMID: 34587127 DOI: 10.14309/ajg.0000000000001263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Hartwig O, Shetab Boushehri MA, Shalaby KS, Loretz B, Lamprecht A, Lehr CM. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. Adv Drug Deliv Rev 2021;175:113828. [PMID: 34157320 DOI: 10.1016/j.addr.2021.113828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
209 Bufman H, Eliakim R, Tau N, Amitai MM. Magnetic resonance enterography in Crohn's disease patients: current state of the art and future perspectives. Expert Rev Med Devices 2021;18:657-67. [PMID: 34109891 DOI: 10.1080/17434440.2021.1939682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
211 Kourkoulis P, Michalopoulos G, Katifelis H, Giannopoulou I, Lazaris AC, Papaconstantinou I, Karamanolis G, Gazouli M. Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. Eur J Gastroenterol Hepatol 2020;32:1106-15. [PMID: 32483088 DOI: 10.1097/MEG.0000000000001783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
212 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
213 Goodsall TM, Costello SP, Bryant RV. Histological Healing in Ulcerative Colitis: Near Enough Is Not Good Enough. J Crohns Colitis 2020;14:1341-2. [PMID: 32602550 DOI: 10.1093/ecco-jcc/jjaa095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Lee J. Classification According to Subjectivity of Inflammatory Bowel Disease Patients Using Q Methodology. Korean J Gastroenterol 2021;78:1-2. [DOI: 10.4166/kjg.2021.103] [Reference Citation Analysis]
215 Park YE, Lee J, Park J, Choi JH, Heo NY, Park SH, Lee YK, Kim TO. Subjective Needs and Thoughts for the Treatment of Patients with Inflammatory Bowel Disease: Applying Q Methodology. Korean J Gastroenterol 2021;78:37-47. [PMID: 34312356 DOI: 10.4166/kjg.2021.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther 2021. [PMID: 34296456 DOI: 10.1111/apt.16544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
217 Knyazev OV, Kagramanova АV, Veselov AV, Skurko TV. Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. City Healthcare 2021;2:65-74. [DOI: 10.47619/2713-2617.zm.2021.v2i2;65-74] [Reference Citation Analysis]
218 Gu P, Chhabra A, Chittajallu P, Chang C, Mendez D, Gilman A, Fudman DI, Xi Y, Feagins LA. Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy. Inflamm Bowel Dis 2021:izab167. [PMID: 34291800 DOI: 10.1093/ibd/izab167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Tsiaoussis GI, Christaki E. Is the APEX Score the Pinnacle of Predictive Scoring Systems of Disease Flare in Crohn's Patients with Documented Mucosal Healing? Dig Dis Sci 2021. [PMID: 34291328 DOI: 10.1007/s10620-021-07154-4] [Reference Citation Analysis]
220 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
221 Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Dig Dis Sci 2021. [PMID: 34286411 DOI: 10.1007/s10620-021-07178-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021. [PMID: 34284522 DOI: 10.1055/a-1504-9782] [Reference Citation Analysis]
223 Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab155. [PMID: 34279600 DOI: 10.1093/ibd/izab155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Yao H, Stidham RW, Gao Z, Gryak J, Najarian K. Motion-based camera localization system in colonoscopy videos. Med Image Anal 2021;73:102180. [PMID: 34303888 DOI: 10.1016/j.media.2021.102180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
225 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
226 Moses J, Sandberg K, Winberry G, Riera D, DeLozier S, Gupta SK, Reilly N, Park KT, Picoraro J. Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. J Pediatr Gastroenterol Nutr 2021;73:61-6. [PMID: 33633082 DOI: 10.1097/MPG.0000000000003100] [Reference Citation Analysis]
227 Norsa L, Ferrari A, Arrigo S, Bramuzzo M, Deganello Saccomani M, Di Nardo G, Illiceto MT, Miele E, Paci M, Romano C, Romeo E, Daperno M, Oliva S; Endoscopy group of the Italian society of pediatric Gastroenterology Hepatology and Nutrition (SIGENP). Scoring Endoscopy in Pediatric Inflammatory Bowel Disease: A Way to Improve Quality. J Pediatr Gastroenterol Nutr 2021;73:48-53. [PMID: 33720096 DOI: 10.1097/MPG.0000000000003090] [Reference Citation Analysis]
228 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
229 Panés J, Vermeire S. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. J Crohns Colitis 2020;14:S711-2. [PMID: 32737980 DOI: 10.1093/ecco-jcc/jjaa109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Kato M, Sugimoto K, Ikeya K, Takano R, Matsuura A, Miyazu T, Ishida N, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Hanai H. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. PLoS One 2021;16:e0254548. [PMID: 34242369 DOI: 10.1371/journal.pone.0254548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Scarallo L, Alvisi P, Bolasco G, Di Toma M, Lanari M, Cangiari A, Paci M, Naldini S, Renzo S, Barp J, De Masi S, Lionetti P. Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha. J Pediatr Gastroenterol Nutr 2021;72:728-35. [PMID: 33399329 DOI: 10.1097/MPG.0000000000003043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
232 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Dolinger MT, Choi JJ, Phan BL, Rosenberg HK, Rowland J, Dubinsky MC. Use of Small Bowel Ultrasound to Predict Response to Infliximab Induction in Pediatric Crohn's Disease. J Clin Gastroenterol 2021;55:429-32. [PMID: 32453126 DOI: 10.1097/MCG.0000000000001367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
234 Vasudevan A, Bruining DH, Loftus EV Jr, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol 2021; 27(25): 3693-3704 [PMID: 34321838 DOI: 10.3748/wjg.v27.i25.3693] [Reference Citation Analysis]
235 Guillo L, Peyrin-Biroulet L, Louis E. Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story? J Crohns Colitis 2021;15:1087-8. [PMID: 33619541 DOI: 10.1093/ecco-jcc/jjab006] [Reference Citation Analysis]
236 Restellini S, Lakatos PL. Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle. J Crohns Colitis 2021;15:1085-6. [PMID: 33515244 DOI: 10.1093/ecco-jcc/jjaa261] [Reference Citation Analysis]
237 Wong ECL, Buffone E, Lee SJ, Dulai PS, Marshall JK, Reinisch W, Narula N. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. J Crohns Colitis 2021;15:1114-9. [PMID: 33245751 DOI: 10.1093/ecco-jcc/jjaa242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
238 Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
239 Narula N, Wong ECL, Colombel JF, Riddell R, Marshall JK, Reinisch W, Dulai PS. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00716-3. [PMID: 34229037 DOI: 10.1016/j.cgh.2021.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
240 Limdi JK, Farraye FA. The Great Debate With IBD Biosimilars. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Click B, Barnes EL, Cohen BL, Sands BE, Hanson JS, Regueiro M, Rubin DT, Dubinsky MC, Gazis DR, Dalfonso L, Hildebrand JS, Crawford JM, Long MD. Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 25.0] [Reference Citation Analysis]
243 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
244 Schnoy E, Messmann H, Kiesslich R. Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen. Gastroenterologe 2021;16:267-277. [DOI: 10.1007/s11377-021-00536-0] [Reference Citation Analysis]
245 Ramos GP, Al-bawardy B, Braga Neto MB, Bledsoe AC, Quinn KP, Heron V, Willrich MAV, Johnson A, Chedid VG, Coelho-prabhu N, Kisiel JB, Papadakis KA, Pardi D, Kane S, Tremaine WJ, Raffals L, Bruining DH, Faubion WA, Harmsen WS, Loftus EV. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab019] [Reference Citation Analysis]
246 Carretero C, Carbonnel F, Ferrante M, Knudsen T, Van Lent N, Lobo AJ, Negreanu L, Vojvodic A, Oliva S. Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. Curr Med Res Opin 2021;37:1547-54. [PMID: 34132150 DOI: 10.1080/03007995.2021.1940910] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, On Behalf Of The EpidemIBD Study Group Of Geteccu. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J Clin Med 2021;10:2885. [PMID: 34209680 DOI: 10.3390/jcm10132885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
248 Lukáš M. Treating inflammatory bowel diseases in the 21<sup>st</sup> century: individualized therapy and telemedicine. Vnitr Lek 2021;67:201-205. [DOI: 10.36290/vnl.2021.053] [Reference Citation Analysis]
249 Helwig U, Fischer I, Hammer L, Kolterer S, Rath S, Maaser C, Kucharzik T. Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets? J Crohns Colitis 2021:jjab106. [PMID: 34185843 DOI: 10.1093/ecco-jcc/jjab106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Luo L, Qing L, Yao C, Liu D, Li Y, Li T, Feng P. Efficacy and safety of hyperbaric oxygen therapy for moderate-to-severe ulcerative colitis: a protocol for a systematic review and meta-analysis. BMJ Open 2021;11:e047543. [PMID: 34183344 DOI: 10.1136/bmjopen-2020-047543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
252 Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Gustavo Kotze P, Peyrin-Biroulet L, Magro F. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00315-7. [PMID: 34187768 DOI: 10.1016/j.dld.2021.05.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Stallard L, Hussey S. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor. Front Pediatr 2021;9:678132. [PMID: 34249815 DOI: 10.3389/fped.2021.678132] [Reference Citation Analysis]
255 Radford SJ, Clarke C, Shinkins B, Leighton P, Taylor S, Moran G. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
256 Buisson A, Filippi J, Amiot A, Cadiot G, Allez M, Marteau P, Bouhnik Y, Pineton de Chambrun G, Pelletier AL, Nancey S, Moussata D, Attar A, Blain A, Vuitton L, Vernier-Massouille G, Seksik P, Nachury M, Dupas JL, Laharie D, Peyrin-Biroulet L, Louis E, Mary JY. Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID. J Crohns Colitis 2021;15:1000-8. [PMID: 33313808 DOI: 10.1093/ecco-jcc/jjaa250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
257 Friedman AB, Asthana A, Knowles SR, Robbins A, Gibson PR. Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:652-66. [PMID: 34157157 DOI: 10.1111/apt.16452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
258 Grandmougin A, D'Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V. Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34159487 DOI: 10.1007/s10620-021-07016-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
260 Kolehmainen S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, Jokiranta TS, Sipponen T. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. Scand J Gastroenterol 2021;56:906-13. [PMID: 34154506 DOI: 10.1080/00365521.2021.1938206] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Yan BM, Sey MSL, Belletrutti P, Brahm G, Guizzetti L, Jairath V. Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis. Endosc Int Open 2021;9:E1116-22. [PMID: 34327283 DOI: 10.1055/a-1481-8032] [Reference Citation Analysis]
262 Pinto Pais I, Espinheira MC, Trindade E, Amil Dias J. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J Pediatr Gastroenterol Nutr 2020;71:12-8. [PMID: 32142005 DOI: 10.1097/MPG.0000000000002704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
263 Hanzel J, Dreesen E, Vermeire S, Löwenberg M, Hoentjen F, Bossuyt P, Clasquin E, Baert FJ, D'Haens GR, Mathôt R. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflamm Bowel Dis 2021:izab143. [PMID: 34137430 DOI: 10.1093/ibd/izab143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
264 Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00642-X. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
266 Vande Casteele N, Leighton JA, Pasha SF, Cusimano F, Mookhoek A, Hagen CE, Rosty C, Pai RK, Pai RK. Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. Inflamm Bowel Dis 2021:izab122. [PMID: 34106256 DOI: 10.1093/ibd/izab122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Jiang Y, Zhao L, Chen Q, Zhou L. Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology. Evid Based Complement Alternat Med 2021;2021:9970240. [PMID: 34211579 DOI: 10.1155/2021/9970240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
268 Ma L, Li W, Zhuang N, Yang H, Liu W, Zhou W, Jiang Y, Li J, Zhu Q, Qian J. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease. Therap Adv Gastroenterol 2021;14:17562848211016259. [PMID: 34178114 DOI: 10.1177/17562848211016259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
269 Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol 2021;6:659-67. [PMID: 34090579 DOI: 10.1016/S2468-1253(21)00096-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
270 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372-84. [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 59.0] [Reference Citation Analysis]
271 Smith SCL, Banbury C, Zardo D, Cannatelli R, Nardone OM, Shivaji UN, Ghosh S, Oppenheimer PG, Iacucci M. Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. PLoS One 2021;16:e0252210. [PMID: 34077453 DOI: 10.1371/journal.pone.0252210] [Reference Citation Analysis]
272 Chen H, Wu L, Wang M, Shao B, Ye L, Zhang Y, Cao Q. Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. Laparoscopic, Endoscopic and Robotic Surgery 2021;4:33-9. [DOI: 10.1016/j.lers.2021.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 Ma C, Sedano R, Almradi A, Vande Casteele N, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology 2021;160:2291-302. [PMID: 33610533 DOI: 10.1053/j.gastro.2021.02.035] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
274 Hu AB, Tan W, Deshpande V, Ananthakrishnan AN. Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn’s Disease in Endoscopic Remission. Clinical Gastroenterology and Hepatology 2021;19:1226-1233.e1. [DOI: 10.1016/j.cgh.2020.04.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
275 Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clinical Gastroenterology and Hepatology 2021;19:1209-1217.e2. [DOI: 10.1016/j.cgh.2020.04.078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
276 Limdi JK, Farraye FA. Automated endoscopic assessment in ulcerative colitis: the next frontier. Gastrointest Endosc 2021;93:737-9. [PMID: 33583524 DOI: 10.1016/j.gie.2020.10.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Núñez F P, Krugliak Cleveland N, Quera R, Rubin DT. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol 2021; 27(20): 2521-2530 [PMID: 34092973 DOI: 10.3748/wjg.v27.i20.2521] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Kapoor A, Crowley E. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:661536. [PMID: 34123968 DOI: 10.3389/fped.2021.661536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
279 Shaffer SR, Erondu AI, Traboulsi C, Rai V, Krugliak Cleveland N, Israel A, Christensen B, Rubin DT. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis 2021:izab130. [PMID: 34037230 DOI: 10.1093/ibd/izab130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
280 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis? Gastroenterol Hepatol 2021:S0210-5705(21)00143-6. [PMID: 34023477 DOI: 10.1016/j.gastrohep.2021.02.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Iacucci M, Jeffery L, Acharjee A, Nardone OM, Zardo D, Smith SCL, Bazarova A, Cannatelli R, Shivaji UN, Williams J, Gkoutos G, Ghosh S. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. Inflamm Bowel Dis 2021:izab059. [PMID: 34019073 DOI: 10.1093/ibd/izab059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
282 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
283 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
284 Lin X, Qiu Y, Feng R, Chen B, He Y, Zeng Z, Zhang S, Chen M, Mao R. Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission. Clin Transl Gastroenterol 2020;11:e00135. [PMID: 32463625 DOI: 10.14309/ctg.0000000000000135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
285 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
286 Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
287 Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
288 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
289 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
290 Lee YJ. Is Paradigm for the Role of Balloon-Assisted Enteroscopy Changing in Crohn's Disease? Gut Liver 2021;15:325-6. [PMID: 33988130 DOI: 10.5009/gnl210194] [Reference Citation Analysis]
291 Mahoro P, Moon HJ, Yang HJ, Kim KA, Cha YS. Protective Effect of Gochujang on Inflammation in a DSS-Induced Colitis Rat Model. Foods 2021;10:1072. [PMID: 34066160 DOI: 10.3390/foods10051072] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
292 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
293 Colombel J, Lakatos PL, Santana GO, Bushmakin AG, Cappelleri JC, Lawendy N, Ponce de Leon D, Kulisek N. Diagnostic accuracy of patient‐reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. GastroHep 2021;3:161-168. [DOI: 10.1002/ygh2.457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Kamperidis N, Fenech V, Thoua N, Cole A, Segal JP, Peake S, Arebi N. Clinical, biomarker and endoscopic outcomes in patients with Crohn’s disease treated with Ustekinumab: Multi‐centre real world study. GastroHep 2021;3:151-160. [DOI: 10.1002/ygh2.453] [Reference Citation Analysis]
295 Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnár T, Szántó K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D'Haens GR, de Vries AC; CEASE Study Group. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00347-5. [PMID: 33933376 DOI: 10.1016/j.cgh.2021.03.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
296 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
297 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 58.0] [Reference Citation Analysis]
298 Allocca M, Craviotto V, Bonovas S, Furfaro F, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S. Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00463-8. [PMID: 33895360 DOI: 10.1016/j.cgh.2021.04.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
299 Tao Z, Zhou X, Zhang Y, Pu W, Yang Y, Wei F, Zhou Q, Zhang L, Du Z, Wu J. Xi Lei San Attenuates Dextran Sulfate Sodium-Induced Colitis in Rats and TNF-α-Stimulated Colitis in CACO2 Cells: Involvement of the NLRP3 Inflammasome and Autophagy. Mediators Inflamm 2021;2021:1610251. [PMID: 33967625 DOI: 10.1155/2021/1610251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
300 Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol 2021;6:482-97. [PMID: 33872568 DOI: 10.1016/S2468-1253(20)30394-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
301 Solitano V, D'Amico F, Allocca M, Fiorino G, Zilli A, Loy L, Gilardi D, Radice S, Correale C, Danese S, Peyrin-Biroulet L, Furfaro F. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? Therap Adv Gastroenterol 2021;14:17562848211005692. [PMID: 33948114 DOI: 10.1177/17562848211005692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
302 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
303 Waked B, Holvoet T, Geldof J, Baert F, Pattyn P, Lobatón T, Hindryckx P. Conservative management of spontaneous intra-abdominal abscess in Crohn's disease: Outcome and prognostic factors. J Dig Dis 2021;22:263-70. [PMID: 33742782 DOI: 10.1111/1751-2980.12984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
304 Osredkar J, Kurent T, Fabjan T, Kumer K, Božnar Alič E, Drobne D. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. Biochem Med (Zagreb) 2021;31:020707. [PMID: 33927557 DOI: 10.11613/BM.2021.020707] [Reference Citation Analysis]
305 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
306 Nardone OM, Manfellotto F, D'Onofrio C, Rocco A, Annona G, Sasso F, De Luca P, Imperatore N, Testa A, de Sire R, Biffali E, Castiglione F. Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease. Nutrients 2021;13:1290. [PMID: 33919766 DOI: 10.3390/nu13041290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
307 Fauny M, D'Amico F, Bonovas S, Netter P, Danese S, Loeuille D, Peyrin-Biroulet L. Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. J Crohns Colitis 2020;14:688-93. [PMID: 31858121 DOI: 10.1093/ecco-jcc/jjz205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
308 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
309 Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis 2021:izab062. [PMID: 33847348 DOI: 10.1093/ibd/izab062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. BMC Gastroenterol 2021;21:161. [PMID: 33845784 DOI: 10.1186/s12876-021-01747-z] [Reference Citation Analysis]
311 Scarallo L, Bolasco G, Barp J, Bianconi M, di Paola M, Di Toma M, Naldini S, Paci M, Renzo S, Labriola F, De Masi S, Alvisi P, Lionetti P. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis 2021:izab046. [PMID: 33835155 DOI: 10.1093/ibd/izab046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 D'Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis 2021:jjab063. [PMID: 33822915 DOI: 10.1093/ecco-jcc/jjab063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
313 Friedman AB. Radiological targets in inflammatory bowel disease: An evolving paradigm. J Gastroenterol Hepatol 2021;36 Suppl 1:10-1. [PMID: 33817844 DOI: 10.1111/jgh.15448] [Reference Citation Analysis]
314 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
315 Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: Are we there yet? J Gastroenterol Hepatol 2021;36 Suppl 1:8-9. [PMID: 33817841 DOI: 10.1111/jgh.15447] [Reference Citation Analysis]
316 Sparrow M. What are the treatment targets in inflammatory bowel disease (IBD) in 2020?: Session one summary. J Gastroenterol Hepatol 2021;36 Suppl 1:4-5. [PMID: 33817846 DOI: 10.1111/jgh.15445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
318 Meserve J, Singh S. Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. Gastroenterology 2021;160:1469-72. [PMID: 33508287 DOI: 10.1053/j.gastro.2021.01.213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
319 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
320 Iacucci M, Smith SCL, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Nardone OM, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology 2021;160:1558-1569.e8. [PMID: 33347880 DOI: 10.1053/j.gastro.2020.12.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
321 Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 29.0] [Reference Citation Analysis]
322 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 402] [Cited by in F6Publishing: 391] [Article Influence: 402.0] [Reference Citation Analysis]
323 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021;44:312-319. [DOI: 10.1016/j.gastre.2020.06.023] [Reference Citation Analysis]
324 Mahlich J, May M, Feig C, Straub V, Schmelz R. Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & Colitis 360 2021;3:otab011. [DOI: 10.1093/crocol/otab011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
325 Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. Medicine (Baltimore) 2021;100:e24925. [PMID: 33725853 DOI: 10.1097/MD.0000000000024925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
326 Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M. Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn´s disease. J Crohns Colitis 2021:jjab055. [PMID: 33773497 DOI: 10.1093/ecco-jcc/jjab055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
327 Soo WT, Costello SP, Bryant RV. Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 33763788 DOI: 10.1007/s10620-021-06946-y] [Reference Citation Analysis]
328 Kessel C, Lavric M, Weinhage T, Brueckner M, de Roock S, Däbritz J, Weber J, Vastert SJ, Foell D. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep 2021;11:6690. [PMID: 33758351 DOI: 10.1038/s41598-021-86251-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
329 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
330 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
331 Estrada DML, Benghi LM, Kotze PG. Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. Curr Opin Gastroenterol 2021;37:320-7. [PMID: 33731643 DOI: 10.1097/MOG.0000000000000737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Navarrete J, González-moret R, Cortés X, Lisón JF, Soria JM, Baños RM, Cebolla A. Dispositional Mindfulness and Inflammatory Bowel Disease: Mindful Awareness Mediates the Relation Between Severity and Quality of Life, Stress, and Fatigue. Mindfulness 2021;12:1524-33. [DOI: 10.1007/s12671-021-01620-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
333 Pinto-Lopes P, Melo F, Afonso J, Pinto-Lopes R, Rocha C, Melo D, Macedo G, Dias CC, Carneiro F, Magro F; Portuguese IBD Study Group (GEDII). Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2021;12:e00320. [PMID: 33704099 DOI: 10.14309/ctg.0000000000000320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
334 Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, Gilleta de Saint-Joseph C, Moreau J, Gonzalez F, Reynaud D, Faure P, Aygalenq P, Combis JM, Peyrin-Biroulet L. Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:530-6. [PMID: 33691075 DOI: 10.1080/00365521.2021.1894602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
335 Bamias G, Kokkotis G, Gizis M, Kapizioni C, Karmiris K, Koureta E, Kyriakos N, Leonidakis G, Makris K, Markopoulos P, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Siakavellas SI, Triantafyllou K, Tsironi E, Tsoukali E, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Zografos K, Papatheodoridis G, Mantzaris G. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Dig Dis Sci 2021. [PMID: 33751325 DOI: 10.1007/s10620-021-06907-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
336 Arkteg CB, Wergeland Sørbye S, Buhl Riis L, Dalen SM, Florholmen J, Goll R. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One 2021;16:e0248224. [PMID: 33684168 DOI: 10.1371/journal.pone.0248224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
337 Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother 2021;138:111427. [PMID: 33706134 DOI: 10.1016/j.biopha.2021.111427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
338 Isoldi S, Cucchiara S, Repici A, Lerner DG, Thomson M, Oliva S. Gastrointestinal endoscopy in children and adults: How do they differ? Dig Liver Dis 2021;53:697-705. [PMID: 33692010 DOI: 10.1016/j.dld.2021.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
339 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
340 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
341 Motta JP, Rolland C, Edir A, Florence AC, Sagnat D, Bonnart C, Rousset P, Guiraud L, Quaranta-Nicaise M, Mas E, Bonnet D, Verdu EF, McKay DM, Buscail E, Alric L, Vergnolle N, Deraison C. Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation. Mucosal Immunol 2021;14:667-78. [PMID: 33674762 DOI: 10.1038/s41385-021-00375-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
342 Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol 2021;15:1091-6. [PMID: 33653185 DOI: 10.1080/17474124.2021.1898944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
343 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
345 Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, Li L, Zeng Z, Chen M, Zhang S. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994741. [PMID: 33717211 DOI: 10.1177/1756284821994741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
346 Azzam N, Aljebreen A, Alharbi O, Charabaty A, Alanazi M, Alkuwaykibi N, Alfaraidi J, Bashamil A, Almansour T, Almadi M. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. Arab J Gastroenterol 2021;22:66-72. [PMID: 33632623 DOI: 10.1016/j.ajg.2021.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Hanzel J, Almradi A, Istl AC, Yang ML, Fleshner KA, Parker CE, Guizzetti L, Ma C, Singh S, Jairath V. Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. Dig Dis Sci 2021. [PMID: 33634430 DOI: 10.1007/s10620-021-06895-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis 2020;14:465-79. [PMID: 31562739 DOI: 10.1093/ecco-jcc/jjz163] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 31.0] [Reference Citation Analysis]
349 Kim AH, Girgis A, De Cruz P, Siegel CA, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. J Med Internet Res 2021;23:e15946. [PMID: 33629956 DOI: 10.2196/15946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
350 Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, Vermeire S, Ferrante M, Dreesen E. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2021;87:3776-89. [PMID: 33604964 DOI: 10.1111/bcp.14785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
351 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
352 Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Kłopocka M, Tarabar D, Vaňásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis 2021;15:938-49. [PMID: 33599720 DOI: 10.1093/ecco-jcc/jjab023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
353 Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr 2021;9:634739. [PMID: 33681110 DOI: 10.3389/fped.2021.634739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, Danese S. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J 2021;9:438-42. [PMID: 33349199 DOI: 10.1177/2050640620980203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
355 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
356 Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2021:izab011. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 18.0] [Reference Citation Analysis]
357 Maldonado-arriaga B, Sandoval-jiménez S, Rodríguez-silverio J, Alcaráz- Estrada SL, Cortés-espinosa T, Pérez-cabeza de Vaca R, Shaw J, Mondragón-terán P, Hernández-cortez C, Suárez-cuenca JA, Castro-escarpulli G. Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico. F1000Res 2021;9:1496. [DOI: 10.12688/f1000research.27629.2] [Reference Citation Analysis]
358 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
359 Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol 2021;116:134-41. [PMID: 33177349 DOI: 10.14309/ajg.0000000000000834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
360 Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1744-53. [PMID: 33450096 DOI: 10.1111/jgh.15401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Gottlieb K, Daperno M, Usiskin K, Sands BE, Ahmad H, Howden CW, Karnes W, Oh YS, Modesto I, Marano C, Stidham RW, Reinisch W. Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut 2021;70:418-26. [PMID: 32699100 DOI: 10.1136/gutjnl-2020-320690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
362 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MDLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterología y Hepatología (English Edition) 2021;44:87-95. [DOI: 10.1016/j.gastre.2020.04.010] [Reference Citation Analysis]
363 Gottlieb K, Requa J, Karnes W, Chandra Gudivada R, Shen J, Rael E, Arora V, Dao T, Ninh A, McGill J. Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks. Gastroenterology 2021;160:710-719.e2. [PMID: 33098883 DOI: 10.1053/j.gastro.2020.10.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 35.0] [Reference Citation Analysis]
364 Visaggi P, Savarino E, Sciume G, Chio TD, Bronzini F, Tolone S, Frazzoni M, Pugno C, Ghisa M, Bertani L, Bellini M, Savarino V, Peroni D, Marchi S, de Bortoli N. Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Therap Adv Gastroenterol 2021;14:1756284820980860. [PMID: 33613690 DOI: 10.1177/1756284820980860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
365 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
366 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
367 Pauwels RWM, van der Woude CJ, Erler NS, de Vries AC. Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therap Adv Gastroenterol 2020;13:1756284820979765. [PMID: 33488771 DOI: 10.1177/1756284820979765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
368 Shiga H, Abe I, Kusaka J, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Kinouchi Y, Masamune A. Capsule Endoscopy Is Useful for Postoperative Tight Control Management in Patients with Crohn's Disease.Dig Dis Sci. 2021;. [PMID: 33495918 DOI: 10.1007/s10620-021-06841-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
369 Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol 2021;15:665-74. [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
370 Zaltman C, Parra RS, Sassaki LY, Santana GO, Ferrari MLA, Miszputen SJ, Amarante HMBS, Kaiser Junior RL, Flores C, Catapani WR, Parente JML, Bafutto M, Ramos O, Gonçalves CD, Guimaraes IM, da Rocha JJR, Feitosa MR, Feres O, Saad-Hossne R, Penna FGC, Cunha PFS, Gomes TN, Nones RB, Faria MAG, Parente MPPD, Scotton AS, Caratin RF, Senra J, Chebli JM. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(2): 208-223 [PMID: 33510560 DOI: 10.3748/wjg.v27.i2.208] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
371 Li XZ, Qiu Y, Jeffery L, Liu F, Feng R, He JS, Tan JY, Ye ZY, Lin SN, Ghosh S, Iacucci M, Chen MH, Mao R. Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Front Med (Lausanne) 2020;7:613475. [PMID: 33511147 DOI: 10.3389/fmed.2020.613475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
372 Miao Z, Chen L, Feng H, Gu M, Yan J, Xu Y, Ye B. Baitouweng Decoction Ameliorates Ulcerative Colitis in Mice Partially Attributed to Regulating Th17/Treg Balance and Restoring Intestinal Epithelial Barrier. Front Pharmacol 2020;11:531117. [PMID: 33597862 DOI: 10.3389/fphar.2020.531117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
373 Ho SSC, Keenan JI, Day AS. Parent Perspectives of Diagnostic and Monitoring Tests Undertaken by Their Child with Inflammatory Bowel Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:19-29. [PMID: 33505890 DOI: 10.5223/pghn.2021.24.1.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Almradi A, Ma C, D'haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
375 Nam K, Park SH, Oh JH, Lee HS, Noh S, Park JC, Kim JY, Oh EH, Kim J, Ham NS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. BMC Gastroenterol 2021;21:13. [PMID: 33407193 DOI: 10.1186/s12876-020-01597-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
376 Snir Y, Iacucci M. The Role of Narrowed Spectrum Technologies and Dye-based Endoscopy in Inflammatory Bowel Disease: New Advances and Opportunities. Techniques and Innovations in Gastrointestinal Endoscopy 2021;23:42-56. [DOI: 10.1016/j.tige.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Katz S, Liu Y. Challenges in the Management of Inflammatory Bowel Disease. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_66] [Reference Citation Analysis]
378 Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP, Chen MH. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut 2021;70:85-91. [PMID: 32576641 DOI: 10.1136/gutjnl-2020-320789] [Cited by in Crossref: 93] [Cited by in F6Publishing: 100] [Article Influence: 93.0] [Reference Citation Analysis]
379 Beraldo RF, Baima JP, Barros JRD, Renosto FL, Saad-hossne R, Sassaki LY. The Impact of a Real-Life Inflammatory Bowel Disease Education Course for Brazilian Physicians from the Perspective of Its Participants. OJGas 2021;11:151-160. [DOI: 10.4236/ojgas.2021.119016] [Reference Citation Analysis]
380 Yamamoto-furusho J, Bosques-padilla F, Martínez-vázquez M. Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista de Gastroenterología de México 2021;86:70-85. [DOI: 10.1016/j.rgmx.2020.10.001] [Reference Citation Analysis]
381 Dotson JL, Boyle B. Crohn Disease. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00042-6] [Reference Citation Analysis]
382 Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2021. [DOI: 10.1007/978-3-030-29964-4_29-1] [Reference Citation Analysis]
383 Yamamoto-furusho J, Bosques-padilla F, Martínez-vázquez M. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. Revista de Gastroenterología de México (English Edition) 2021;86:70-85. [DOI: 10.1016/j.rgmxen.2020.10.007] [Reference Citation Analysis]
384 Sultan K, Becher N. Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_3] [Reference Citation Analysis]
385 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Mackiewicz T, Sowa A, Fichna J. Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. Curr Drug Targets 2021;22:137-45. [PMID: 32077822 DOI: 10.2174/1389450121666200220123844] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Steenholdt C, Jensen JT, Brynskov J, Møller AM, Limschou AC, Konge L, Vilmann P. Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31495-6. [PMID: 33371995 DOI: 10.1016/j.cgh.2020.10.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
388 Abdulganieva DI, Bakulev AL, Belousova EA, Veselov AV, Korotaeva TV, Lila AM, Loginova EY, Sokolovskiy EV, Khobeysh MM, Shapina MV, Shchukina OB. Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion. Alʹm klin med 2020;48:422-436. [DOI: 10.18786/2072-0505-2020-48-050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
390 Torres J, Declerck P. Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. Curr Opin Pharmacol 2020;55:iii-vi. [PMID: 33357460 DOI: 10.1016/j.coph.2020.12.004] [Reference Citation Analysis]
391 Nishikawa T, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M. Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn's disease. J Gastroenterol Hepatol 2021;36:1851-8. [PMID: 33283324 DOI: 10.1111/jgh.15366] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
392 Maldonado-arriaga B, Sandoval-jiménez S, Rodríguez-silverio J, Alcaráz- Estrada SL, Cortés-espinosa T, Pérez-cabeza de Vaca R, Shaw J, Mondragón-terán P, Hernández-cortez C, Suárez-cuenca JA, Castro-escarpulli G. Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico. F1000Res 2020;9:1496. [DOI: 10.12688/f1000research.27629.1] [Reference Citation Analysis]
393 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
394 Vilela EG, Rocha HC, Moraes AC, Santana GO, Parente JM, Sassaki LY, Miszputen SJ, Quaresma AB, Clara APHS, Jesus ACS, Pinto ADS, Silva BLPSD, Silva BCD, Freire CCF, Santos CHMD, Brito C, Teixeira EFL, Miranda EF, Zabot GP, Duarte JL, Ludvig JC, Campos-Lobato LF, Cassol OS, Souza MM, Almeida NP, Parra RS, Lima JÚnior SF, Saad-Hossne R. INFLAMMATORY BOWEL DISEASE CARE IN BRAZIL: HOW IT IS PERFORMED, OBSTACLES AND DEMANDS FROM THE PHYSICIANS' PERSPECTIVE. Arq Gastroenterol 2020;57:416-27. [PMID: 33331475 DOI: 10.1590/S0004-2803.202000000-77] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
395 Rahmi G, Coron E, Perrod G, Levy M, Moreau J, Moussata D, Perez-Cuadrado-Robles E, Chupin A, Quénéhervé L, Bourreille A, Marchal A, Cellier C, Peyrin-Biroulet L. Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index. J Crohns Colitis 2021;15:994-9. [PMID: 33336249 DOI: 10.1093/ecco-jcc/jjaa255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
396 Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31674-8. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
397 Patel DB, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. Inflammatory Bowel Diseases 2021;27:1593-601. [DOI: 10.1093/ibd/izaa311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
398 Zuluaga Arbeláez N, Sierra Vargas EC, Díaz Coronado JC, Guevara Casallas LG. Colitis ulcerativa para no gastroenterólogos. CES Med 2020;34:188-197. [DOI: 10.21615/cesmedicina.34.3.2] [Reference Citation Analysis]
399 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
400 Christensen B, Rubin DT. Reply. Clin Gastroenterol Hepatol 2021;19:2452-4. [PMID: 33278575 DOI: 10.1016/j.cgh.2020.11.044] [Reference Citation Analysis]
401 Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis. 2020;. [PMID: 33269403 DOI: 10.1093/ibd/izaa309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
402 Yamamoto-Furusho JK, Martínez-Benítez B, Sánchez-Morales GE. Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. Gastroenterol Res Pract 2020;2020:8891937. [PMID: 33343656 DOI: 10.1155/2020/8891937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
403 Puyade M, Treton X, Alric L, Badoglio M, Castilla Llorente C, Fotsing G, Marjanovic Z, Rovira M, Terriou L, Torregrosa Díaz Jose M, Tran-minh M, Allez M, Pugnet G, Laharie D, Yakoub-agha I, Farge D. Indications de l’autogreffe de cellules hématopoïétiques dans la Maladie de Crohn : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire. Bulletin du Cancer 2020;107:S140-50. [DOI: 10.1016/j.bulcan.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
404 Abreu MT, Sandborn WJ; IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology 2020;159:2013-2018.e7. [PMID: 32961246 DOI: 10.1053/j.gastro.2020.07.064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
405 Juliao-baños F, Grillo A CF, Pineda Ovalle LF, Otero Regino. W, Galiano de Sánchez. MT, García Duperly. R, Vallejo O. MT, Torres Amaya. M. Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta. Rev Colomb Gastroenterol 2020;35:63-200. [DOI: 10.22516/25007440.637] [Reference Citation Analysis]
406 Debnath P, Rathi P. Outcomes Related to Mucosal Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2021;19:2214. [PMID: 33248102 DOI: 10.1016/j.cgh.2020.10.049] [Reference Citation Analysis]
407 Tadbiri S, Nachury M, Bouhnik Y, Serrero M, Hébuterne X, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, ABitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Dib N, Brixi H, Boualit M, Plastaras L, Boivineau L, Fumery M, Caillo L, Laharie D, Amiot A; GETAID-IBD-disk study group . The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. J Crohns Colitis 2021;15:766-73. [PMID: 33246337 DOI: 10.1093/ecco-jcc/jjaa244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
408 Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis 2021;27:1277-84. [PMID: 33236763 DOI: 10.1093/ibd/izaa301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 52.0] [Reference Citation Analysis]
410 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
411 Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intest Res 2021;19:408-18. [PMID: 33207857 DOI: 10.5217/ir.2020.00025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
412 Kotze PG, DamiÃo AOMC. Research in inflammatory bowel disease in Brazil: a step forward towards patient care. Arq Gastroenterol 2020;57:225-6. [PMID: 33206810 DOI: 10.1590/S0004-2803.202000000-43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
413 Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A; GETAID-patient experience study group. Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Dig Liver Dis 2021;53:434-41. [PMID: 33187920 DOI: 10.1016/j.dld.2020.10.020] [Reference Citation Analysis]
414 Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L; French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis 2021;53:35-43. [PMID: 33160886 DOI: 10.1016/j.dld.2020.10.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
415 van Hoeve K, Vermeire S. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatr Drugs 2020;22:449-61. [PMID: 32797366 DOI: 10.1007/s40272-020-00411-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
416 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
417 Haar GS, Vasudevan A, Curtain CM, van Langenberg DR. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. Res Social Adm Pharm 2021;17:1420-5. [PMID: 33129684 DOI: 10.1016/j.sapharm.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 van der Laan JJH, van der Waaij AM, Gabriëls RY, Festen EAM, Dijkstra G, Nagengast WB. Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. Expert Rev Gastroenterol Hepatol 2021;15:115-26. [PMID: 33094654 DOI: 10.1080/17474124.2021.1840352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
419 Heron V, Loftus EV Jr. Nonbiologic Immune Suppression in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:731-8. [PMID: 33121692 DOI: 10.1016/j.gtc.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
420 Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opin Biol Ther 2021;21:97-104. [PMID: 33074723 DOI: 10.1080/14712598.2020.1839045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
421 Batra S, Conklin LS. Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm. Handb Exp Pharmacol 2020;261:363-75. [PMID: 31342277 DOI: 10.1007/164_2019_255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
422 Buisson A, Mak WY, Andersen MJ, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis 2021;27:1008-16. [PMID: 33107563 DOI: 10.1093/ibd/izaa269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
423 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
424 Kader R, Dart RJ, Sebepos‐rogers G, Shakweh E, Middleton P, Mcguire J, Pavlidis P, Ahmad OF, Segal J, Samaan MA, Gahir J, Black G, Theaker H, Calderbank T, Meade S, Ibraheim H, Clough J, Bancil A, Honap S, Hampal R, Tavabie O, Tai C, Tern P, Akbar S, Patel R, Rhead C, Kabir M, Bashyam M, Fofaria R, Hiner G, Ravindran S, Walton H, King J, Dhillon A, Seller P, Mukherjee S, Harlow C; GLINT Research Network. Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting. GastroHep 2020;2:309-17. [DOI: 10.1002/ygh2.427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
425 Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, Allocca M, Maconi G, de Voogd F, Christensen B, Vaughan R, Palmela C, Carter D, Wilkens R. Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. J Crohns Colitis 2021;15:609-16. [PMID: 33098642 DOI: 10.1093/ecco-jcc/jjaa216] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
426 Papa A, Papa V, Lopetuso LR, Gasbarrini A, Tursi A. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therap Adv Gastroenterol 2020;13:1756284820968747. [PMID: 33149764 DOI: 10.1177/1756284820968747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Kornbluth A. Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? Inflamm Bowel Dis 2020;26:1730-2. [PMID: 32031216 DOI: 10.1093/ibd/izz333] [Reference Citation Analysis]
428 Dal Piaz G, Mendolaro M, Mineccia M, Randazzo C, Massucco P, Cosimato M, Rigazio C, Guiotto C, Morello E, Ercole E, Lavagna A, Rocca R, Ferrero A, Daperno M. Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series. Dig Liver Dis 2021;53:987-95. [PMID: 33526411 DOI: 10.1016/j.dld.2020.09.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
429 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
430 Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M. Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:864-72. [PMID: 33002235 DOI: 10.1111/jgh.15288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
431 Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease. Inflamm Intest Dis 2020;5:212-20. [PMID: 33313074 DOI: 10.1159/000510682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
432 Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?Curr Opin Pharmacol. 2020;55:17-30. [PMID: 33039940 DOI: 10.1016/j.coph.2020.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
433 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 57.5] [Reference Citation Analysis]
434 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
435 Rönnblom A, Karlbom U. Clinical course of Crohn’s disease in a population-based cohort in Uppsala County followed for 10 years. Scandinavian Journal of Gastroenterology 2020;55:1301-7. [DOI: 10.1080/00365521.2020.1829700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Kumar A, Kim ES, Kozan P, Jacob V, Longman RS, Scherl EJ, Battat RJ, Lukin DJ. Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa074] [Reference Citation Analysis]
437 Limdi JK. Indian Journal of Gastroenterology September-October 2020. Indian J Gastroenterol 2020;39:415-8. [PMID: 33226569 DOI: 10.1007/s12664-020-01120-0] [Reference Citation Analysis]
438 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
439 Pai RK, Hartman DJ, Rivers CR, Regueiro M, Schwartz M, Binion DG, Pai RK. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2510-2517.e5. [DOI: 10.1016/j.cgh.2019.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
440 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
441 Mastronardi M, Curlo M, Polignano M, Vena N, Rossi D, Giannelli G. Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic. Healthcare (Basel). 2020;8. [PMID: 33019563 DOI: 10.3390/healthcare8040377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
442 Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut 2020;69:1778-86. [PMID: 31915237 DOI: 10.1136/gutjnl-2019-320056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 21.5] [Reference Citation Analysis]
443 Haisma SM, Verkade HJ, Scheenstra R, van der Doef HPJ, Bodewes FAJA, van Rheenen PF. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:466-73. [PMID: 31365486 DOI: 10.1097/MPG.0000000000002458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
444 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
445 Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol 2020;115:885-94. [PMID: 32384283 DOI: 10.14309/ajg.0000000000000596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
446 Khorshid M, Bakheet N, Abdallah S, Essam M, Cordie A. COVID-19: A strong call for remote medicine in inflammatory bowel disease. J Dig Dis. 2020;21:597-599. [PMID: 32888261 DOI: 10.1111/1751-2980.12935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
447 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
448 Abdulganieva DI, Bakulev AL, Belousova EA, Veselov AV, Korotaeva TV, Lila AM, Loginova EY, Sokolovskiy EV, Khobeish MM, Shapina MV, Shchukina OB. Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion. Sovremennaâ revmatologiâ 2020;14:7-18. [DOI: 10.14412/1996-7012-2020-3-7-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
449 Colman RJ, Tsai YT, Jackson K, Boyle BM, Noe JD, Hyams JS, D'Haens GRAM, van Limbergen J, Rosen MJ, Denson LA, Minar P. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflamm Bowel Dis 2021;27:1045-51. [PMID: 32944769 DOI: 10.1093/ibd/izaa241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
450 Biscaglia G, Piazzolla M, Cocomazzi F, Melchionda G, De Cata A, Bossa F, Palmieri O, Andriulli A. Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology & Hepatology 2020;32:1579-82. [DOI: 10.1097/meg.0000000000001919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
451 Taylor H, Serrano-Contreras JI, McDonald JAK, Epstein J, Fell JM, Seoane RC, Li JV, Marchesi JR, Hart AL. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Aliment Pharmacol Ther 2020;52:1491-502. [PMID: 32929796 DOI: 10.1111/apt.16086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
452 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 260] [Cited by in F6Publishing: 276] [Article Influence: 130.0] [Reference Citation Analysis]
453 Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MAM, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L, Torres J, Santiago M, Estevinho MM, Danese S, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31274-X. [PMID: 32920215 DOI: 10.1016/j.cgh.2020.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
454 Fournier AP, Martinez de Lizarrondo S, Rateau A, Gerard-brisou A, Waldner MJ, Neurath MF, Vivien D, Docagne F, Gauberti M. Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. Sci Transl Med 2020;12:eaaz4047. [DOI: 10.1126/scitranslmed.aaz4047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
455 Scaldaferri F, Ianiro G, Privitera G, Lopetuso LR, Vetrone LM, Petito V, Pugliese D, Neri M, Cammarota G, Ringel Y, Costamagna G, Gasbarrini A, Boskoski I, Armuzzi A. The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflamm Bowel Dis. 2020;26:1306-1314. [PMID: 32720978 DOI: 10.1093/ibd/izaa181] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
456 Fahad H, Abu-Elmagd K, Lashner B, Fiocchi C. Recurrence of Crohn's Disease After Small Bowel Transplantation: Fact or Fiction. Inflamm Bowel Dis 2020;26:21-3. [PMID: 31634393 DOI: 10.1093/ibd/izz248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
457 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
458 Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther 2020;52:1563-73. [PMID: 32886809 DOI: 10.1111/apt.16069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
459 Matsubayashi M, Kobayashi T, Okabayashi S, Nakano M, Sagami S, Ozaki R, Kiyohara H, Morikubo H, Asonuma K, Miyatani Y, Maeda S, Hibi T. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. J Gastroenterol Hepatol 2021;36:943-50. [PMID: 32805065 DOI: 10.1111/jgh.15220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
460 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
461 Maaser C, Petersen F, Helwig U, Fischer I, Roessler A, Rath S, Lang D, Kucharzik T; German IBD Study Group and the TRUST&UC study group., German IBD Study Group and TRUST&UC study group. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut 2020;69:1629-36. [PMID: 31862811 DOI: 10.1136/gutjnl-2019-319451] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 32.5] [Reference Citation Analysis]
462 Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 2021;21:37-46. [PMID: 32799561 DOI: 10.1080/14712598.2020.1811849] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
463 Lee J. Clinical Application of Artificial Intelligence to Evaluate Disease Activity in Patients with Ulcerative Colitis. Korean J Gastroenterol 2020;76:97-98. [DOI: 10.4166/kjg.2020.76.2.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
464 Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis 2020;26:1429-35. [PMID: 31748806 DOI: 10.1093/ibd/izz276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
465 Gecse KB, Buskens CJ. Implication of Medical Treatment for Surgical Strategies in IBD. Curr Drug Targets 2019;20:1363-8. [PMID: 31113342 DOI: 10.2174/1389450120666190515095520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
466 Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
467 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
468 Krzystek-Korpacka M, Kempiński R, Bromke MA, Neubauer K. Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review. Diagnostics (Basel) 2020;10:E601. [PMID: 32824619 DOI: 10.3390/diagnostics10080601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
469 Yao H, Najarian K, Gryak J, Bishu S, Rice MD, Waljee AK, Wilkins HJ, Stidham RW. Fully automated endoscopic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2021;93:728-736.e1. [PMID: 32810479 DOI: 10.1016/j.gie.2020.08.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
470 Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
471 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
472 Stevens TW, Gecse K, Turner JR, de Hertogh G, Rubin DT, D'Haens GR. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31128-9. [PMID: 32801008 DOI: 10.1016/j.cgh.2020.08.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
473 Wang JJ, Fan YH, Huang R. Strengthened monitoring and optimized management of Crohn's disease patients. Shijie Huaren Xiaohua Zazhi 2020; 28(15): 660-668 [DOI: 10.11569/wcjd.v28.i15.660] [Reference Citation Analysis]
474 Borren NZ, Plichta D, Joshi AD, Bonilla G, Sadreyev R, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis 2020;26:1524-32. [PMID: 32766830 DOI: 10.1093/ibd/izaa183] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
475 Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:908-921.e6. [PMID: 32777549 DOI: 10.1016/j.cgh.2020.07.067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
476 Melek J, Štanclová M, Dědek P, Malý J, Bayer M, Pozler O, Bureš J. Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease. J Dig Dis 2020;21:705-10. [PMID: 32755026 DOI: 10.1111/1751-2980.12927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
477 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
478 Langhorst J, Umutlu L, Schaarschmidt BM, Grueneisen J, Demircioglu A, Forsting M, Beiderwellen K, Haubold J, Theysohn JM, Koch AK, Dobos G, Dechêne A, Herrmann K, Bruckmann NM, Lauenstein T, Li Y. Diagnostic Performance of Simultaneous [18F]-FDG PET/MR for Assessing Endoscopically Active Inflammation in Patients with Ulcerative Colitis: A Prospective Study. J Clin Med 2020;9:E2474. [PMID: 32752196 DOI: 10.3390/jcm9082474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
479 Cazelles A, Panis Y, Treton X. Le recours à la chirurgie est‑il parfois trop tardif dans le cadre des MICI ? Colon Rectum 2020;14:159-166. [DOI: 10.3166/cer-2020-0147] [Reference Citation Analysis]
480 Zorzi F, Ghosh S, Chiaramonte C, Lolli E, Ventura M, Onali S, De Cristofaro E, Fantini MC, Biancone L, Monteleone G, Calabrese E. Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn’s Disease. Clinical Gastroenterology and Hepatology 2020;18:2030-7. [DOI: 10.1016/j.cgh.2019.10.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
481 Shin J, Kong SM, Seong G, Kim YH. What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission? Int J Colorectal Dis 2020;35:2249-55. [PMID: 32749515 DOI: 10.1007/s00384-020-03705-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
482 Wright EK, Wang I, Wong D, Bell SJ, Connell WR, Thompson AJ, Novak KL, Kamm MA. Accuracy of point-of-care intestinal ultrasound for Crohn's disease. Australas J Ultrasound Med 2020;23:176-82. [PMID: 34760597 DOI: 10.1002/ajum.12218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
483 Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, Danese S. Point-of-Care Ultrasound in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:143-51. [PMID: 32674146 DOI: 10.1093/ecco-jcc/jjaa151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
484 Verdon C, Reinglas J, Coulombe J, Gonczi L, Bessissow T, Afif W, Vutcovici M, Wild G, Seidman EG, Bitton A, Brassard P, Lakatos PL. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015. Inflamm Bowel Dis 2021;27:655-61. [PMID: 32676662 DOI: 10.1093/ibd/izaa166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
485 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
486 Yen HH, Chen MW, Chang YY, Huang HY, Hsu TC, Chen YY. Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis. PeerJ 2020;8:e9537. [PMID: 32742803 DOI: 10.7717/peerj.9537] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
487 Vasant DH, Ford AC. Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift? World J Gastroenterol 2020; 26(26): 3712-3719 [PMID: 32774052 DOI: 10.3748/wjg.v26.i26.3712] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
488 Nakase H, Matsumoto T, Watanabe K, Hisamatsu T. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. J Gastroenterol 2020;55:824-32. [PMID: 32661927 DOI: 10.1007/s00535-020-01702-x] [Reference Citation Analysis]
489 Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clin Gastroenterol Hepatol 2021;19:1366-1376.e2. [PMID: 32668338 DOI: 10.1016/j.cgh.2020.07.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
490 Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20:211. [PMID: 32640990 DOI: 10.1186/s12876-020-01332-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
491 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
492 Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR; Etrolizumab Global Steering Committee. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther 2020;37:3417-31. [PMID: 32445184 DOI: 10.1007/s12325-020-01366-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 17.5] [Reference Citation Analysis]
493 Annese V, Lakatos PL. A further “stri(v)de” in IBD management. Digestive and Liver Disease 2020;52:721-722. [DOI: 10.1016/j.dld.2020.02.005] [Reference Citation Analysis]
494 Ricci L, Epstein J, Buisson A, Devos C, Toussaint Y, Peyrin-Biroulet L, Guillemin F. Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol. BMJ Open 2020;10:e037211. [PMID: 32611745 DOI: 10.1136/bmjopen-2020-037211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
495 Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology 2020;159:139-47. [PMID: 32224129 DOI: 10.1053/j.gastro.2020.03.039] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 37.5] [Reference Citation Analysis]
496 Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol 2020;5:900-7. [PMID: 32619413 DOI: 10.1016/S2468-1253(20)30117-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
497 Popa DE, Manea NC, Gheonea DI, PÎrlog MC. Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. Curr Health Sci J 2020;46:103-10. [PMID: 32874680 DOI: 10.12865/CHSJ.46.02.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
498 Deepak P, Itani M. Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Aliment Pharmacol Ther 2020;52:401-2. [PMID: 32592259 DOI: 10.1111/apt.15816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
499 Cannatelli R, Bazarova A, Zardo D, Nardone OM, Shivaji U, Smith SCL, Gkoutos G, Ricci C, Gui XS, Ghosh S, Iacucci M. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflamm Bowel Dis. 2020;. [PMID: 32592477 DOI: 10.1093/ibd/izaa163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
500 Li Y, Khamou M, Schaarschmidt BM, Umutlu L, Forsting M, Demircioglu A, Haubold J, Koch AK, Bruckmann NM, Sawicki LM, Herrmann K, Boone JH, Langhorst J. Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. Br J Radiol 2020;93:20200167. [PMID: 32579403 DOI: 10.1259/bjr.20200167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
501 Zilli A, Capogreco A, Furfaro F, Allocca M, Roda G, Loy L, Fiorino G, Danese S. Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? Expert Rev Gastroenterol Hepatol. 2020;14:819-828. [PMID: 32543983 DOI: 10.1080/17474124.2020.1780913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
502 Bogdanov АN, Gorbunova EV, Goryachev DV, Petraneva EV. Current Approaches to Planning and Conducting Clinical Trials of Medicinal Products for the Treatment of Crohn's Disease. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2020;10:111-120. [DOI: 10.30895/1991-2919-2020-10-2-111-120] [Reference Citation Analysis]
503 Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S, Allocca M. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? Expert Rev Gastroenterol Hepatol 2020;14:775-87. [PMID: 32515627 DOI: 10.1080/17474124.2020.1780914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
504 Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, Watschinger C, Koch R, Effenberger M, Raine T, Tilg H, Moschen AR. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2—a Comparative Study. Journal of Crohn's and Colitis 2021;15:43-54. [DOI: 10.1093/ecco-jcc/jjaa124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
505 Grossman A, Mauer E, Gerber LM, Long MD, Kappelman MD, Gupta N. Black/African American Patients with Pediatric Crohn's Disease Report Less Anxiety and Fatigue than White Patients. J Pediatr 2020;225:146-51. [PMID: 32544479 DOI: 10.1016/j.jpeds.2020.05.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
506 D'Amico F, Peyrin-Biroulet L, Vandromme L, Bouhnik Y, Faure P, Nahon S, Hagege H, Hebuterne X, Benkhalifa S, Nachury M. Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study. Dig Liver Dis 2020;52:995-1001. [PMID: 32532602 DOI: 10.1016/j.dld.2020.05.032] [Reference Citation Analysis]
507 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
508 Glassner K, Oglat A, Duran A, Koduru P, Perry C, Wilhite A, Abraham BP. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis 2020;21:264-71. [DOI: 10.1111/1751-2980.12867] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
509 Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S, Peyrin-Biroulet L. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020;17:507-516. [PMID: 32528139 DOI: 10.1038/s41575-020-0319-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
510 Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Baglietto L, de Bortoli N, Bellini M, Marchi S, Costa F, Blandizzi C. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther 2020;52:284-91. [PMID: 32506635 DOI: 10.1111/apt.15870] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
511 Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results. World J Gastroenterol 2020; 26(21): 2852-2863 [PMID: 32550760 DOI: 10.3748/wjg.v26.i21.2852] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Frimor C, Kjeldsen J, Ainsworth M. Treatment to target in patients with inflammatory bowel disease. What is the evidence? Scand J Gastroenterol 2020;55:528-36. [PMID: 32503364 DOI: 10.1080/00365521.2020.1764091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
513 Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther 2020;52:292-302. [PMID: 32506695 DOI: 10.1111/apt.15808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
514 Calabrese C, Diegoli M, Dussias N, Salice M, Rizzello F, Cappelli A, Ricci C, Gionchetti P. Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn’s Disease. Crohn's & Colitis 360 2020;2:otaa046. [DOI: 10.1093/crocol/otaa046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
515 Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. Br J Clin Pharmacol 2021;87:106-18. [PMID: 32415677 DOI: 10.1111/bcp.14364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
516 Editorial A. CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). Koloproktologiâ 2020;19:8-38. [DOI: 10.33878/2073-7556-2020-19-2-8-38] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
517 D'Amico F, Chateau T, Laurent V, Danese S, Peyrin-Biroulet L. Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity? J Clin Med 2020;9:E1691. [PMID: 32498279 DOI: 10.3390/jcm9061691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
518 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
519 Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F. Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis 2019;25:S24-30. [PMID: 31095703 DOI: 10.1093/ibd/izz077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
520 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
521 Won J, Lee B, Jung W, Chae Y, Lee H. Herbal medicine for inflammatory bowel diseases: development of pattern identification algorithms by retrospective analysis of case series data. European Journal of Integrative Medicine 2020;36:101114. [DOI: 10.1016/j.eujim.2020.101114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
522 Holmer AK, Dulai PS. Using Artificial Intelligence to Identify Patients With Ulcerative Colitis in Endoscopic and Histologic Remission. Gastroenterology 2020;158:2045-7. [PMID: 32289374 DOI: 10.1053/j.gastro.2020.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
523 Queiroz NSF, Yamamoto T, Kotze PG. Optimal strategies to prevent recrudescent Crohn's disease after resection. Seminars in Colon and Rectal Surgery 2020;31:100746. [DOI: 10.1016/j.scrs.2020.100746] [Reference Citation Analysis]
524 Sulz MC, Duetschler J, Seibold F. Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag. Schweiz Gastroenterol 2020;1:51-64. [DOI: 10.1007/s43472-020-00009-9] [Reference Citation Analysis]
525 Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1828-37. [PMID: 31039246 DOI: 10.1093/ibd/izz081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
526 Mavropoulou E, Mechie NC, Knoop R, Petzold G, Ellenrieder V, Kunsch S, Pilavakis Y, Amanzada A. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. PLoS One. 2020;15:e0233811. [PMID: 32470973 DOI: 10.1371/journal.pone.0233811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
527 Apine I, Pitura R, Franckevica I, Pokrotnieks J, Krumina G. Comparison between Diffusion-Weighted Sequences with Selective and Non-Selective Fat Suppression in the Evaluation of Crohn's Disease Activity: Are They Equally Useful? Diagnostics (Basel) 2020;10:E347. [PMID: 32471191 DOI: 10.3390/diagnostics10060347] [Reference Citation Analysis]
528 Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol 2020;55:656-63. [PMID: 32442051 DOI: 10.1080/00365521.2020.1768282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
529 Dulai PS, Sandborn WJ, Murphy J. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1170-1179.e10. [PMID: 32437872 DOI: 10.1016/j.cgh.2020.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Huang S, Li L, Ben-Horin S, Mao R, Lin S, Qiu Y, Feng R, He Y, Chen B, Zeng Z, Chen M, Zhang S. Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. Clin Transl Gastroenterol 2019;10:e00015. [PMID: 30839440 DOI: 10.14309/ctg.0000000000000015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
531 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
532 Ben Nessib D, Ferjani H, Maatallah K, Rahmouni S, Kaffel D, Hamdi W. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol 2020;39:3543-53. [PMID: 32424656 DOI: 10.1007/s10067-020-05136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
533 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
534 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
535 Sandberg K, Yarger E, Saeed S. Updates in diagnosis and management of inflammatory bowel disease.Curr Probl Pediatr Adolesc Health Care. 2020;50:100785. [PMID: 32402535 DOI: 10.1016/j.cppeds.2020.100785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
536 Srinivasan A, van Langenberg DR, Little RD, Sparrow MP, De Cruz P, Ward MG. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn’s disease. Aliment Pharmacol Ther 2020;51:1342-52. [DOI: 10.1111/apt.15742] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
537 Liu P, Bian Y, Liu T, Zhong J, Zhong Y, Zhuang S, Liu Z. Huai hua san alleviates dextran sulphate sodium-induced colitis and modulates colonic microbiota. J Ethnopharmacol 2020;259:112944. [PMID: 32387236 DOI: 10.1016/j.jep.2020.112944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
538 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
539 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
540 Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, Vandecasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D’haens GR, Jairath V. Response to Placebo, Measured by Endoscopic Evaluation of Crohn’s Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clinical Gastroenterology and Hepatology 2020;18:1121-1132.e2. [DOI: 10.1016/j.cgh.2019.08.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
541 Salameh R, Kirchgesner J, Allez M, Carbonnel F, Meyer A, Gornet JM, Beaugerie L, Amiot A. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther 2020;51:1096-104. [PMID: 32342994 DOI: 10.1111/apt.15751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
542 Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
543 Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis 2019;25:1399-407. [PMID: 30689871 DOI: 10.1093/ibd/izy400] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
544 Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intest Res 2021;19:53-61. [PMID: 32312035 DOI: 10.5217/ir.2019.09146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
545 Sexton KA, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie BE, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN. The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflamm Bowel Dis 2019;25:1277-90. [PMID: 30918969 DOI: 10.1093/ibd/izz038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
546 Fukuda T, Naganuma M, Takabayashi K, Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Mutaguchi M, Inoue N, Ogata H, Iwao Y, Abe T, Kanai T. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. J Gastroenterol Hepatol 2020;35:1878-85. [PMID: 32250471 DOI: 10.1111/jgh.15059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
547 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
548 Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598-606. [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 31.0] [Reference Citation Analysis]
549 Le Berre C, Bourreille A, Flamant M, Bouguen G, Siproudhis L, Dewitte M, Dib N, Cesbron-Metivier E, Goronflot T, Hanf M, Gourraud PA, Kerdreux E, Poinas A, Trang-Poisson C. Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study. BMC Gastroenterol 2020;20:110. [PMID: 32299390 DOI: 10.1186/s12876-020-01246-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
550 Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet J, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M; UC-USK-GETAID Study Group. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther 2020;51:1039-46. [DOI: 10.1111/apt.15717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
551 van Deen WK, Kiaei B, Weaver SA, Crate DJ, Kwon MH, Shah SA, Melmed GY, Siegel CA. A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. Qual Life Res 2020;29:2403-14. [PMID: 32279196 DOI: 10.1007/s11136-020-02492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
552 Mandl P, Aletaha D. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford) 2019;58:2091-8. [PMID: 31518423 DOI: 10.1093/rheumatology/kez397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
553 Chao CY, Lemieux C, Restellini S, Afif W, Bitton A, Lakatos PL, Wild G, Bessissow T. Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease. Saudi J Gastroenterol 2019;25:159-66. [PMID: 30900609 DOI: 10.4103/sjg.SJG_566_18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
554 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 162] [Cited by in F6Publishing: 172] [Article Influence: 81.0] [Reference Citation Analysis]
555 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
556 Cao R, Ma Y, Li S, Shen D, Yang S, Wang X, Cao Y, Wang Z, Wei Y, Li S, Liu G, Zhang H, Wang Y, Ma Y. 1,25(OH)2 D3 alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation. J Leukoc Biol 2020;108:283-95. [PMID: 32237257 DOI: 10.1002/JLB.3MA0320-406RR] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
557 Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut 2020;69:658-64. [PMID: 31285357 DOI: 10.1136/gutjnl-2019-318256] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
558 Verdon C, Vande Casteele N, Heron V, Germain P, Afif W. Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease. J Can Assoc Gastroenterol 2021;4:73-7. [PMID: 33855264 DOI: 10.1093/jcag/gwaa003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
559 Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Brombin C, de Bortoli N, Bellini M, Marchi S, Bodini G, Savarino E, Costa F. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020;26:1579-1587. [PMID: 32232392 DOI: 10.1093/ibd/izaa062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
560 Li Y, Langhorst J, Koch AK, Demircioglu A, Schaarschmidt B, Theysohn JM, Martin O, Herrmann K, Catalano O, Umutlu L. Comparison of acceptance of PET/MR enterography and ileocolonoscopy in patients with inflammatory bowel diseases. Clin Imaging 2020;64:11-7. [PMID: 32200275 DOI: 10.1016/j.clinimag.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
561 Iacucci M, Cannatelli R, Gui X, Zardo D, Bazarova A, Gkoutos GV, Lethebe BC, Kaplan GG, Panaccione R, Kiesslich R, Ghosh S. Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative Colitis. Journal of Crohn's and Colitis 2020;14:1282-9. [DOI: 10.1093/ecco-jcc/jjaa056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
562 Rottenstreich A, Mishael T, Granovsky SG, Koslowsky B, Schweistein H, Abitbol G, Goldin E, Shitrit AB. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020;77:105-10. [PMID: 32197833 DOI: 10.1016/j.ejim.2020.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
563 Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther 2020;51:852-60. [PMID: 32201971 DOI: 10.1111/apt.15680] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
564 Moore AC, Huang VW, Bourdages R, Fedorak RN, Reinhard C, Leung Y, Bressler B, Rosenfeld G. IBDoc Canadian User Performance Evaluation. Inflamm Bowel Dis 2019;25:1107-14. [PMID: 30535387 DOI: 10.1093/ibd/izy357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
565 Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1028-35. [PMID: 30365009 DOI: 10.1093/ibd/izy323] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
566 Fukaura K, Iboshi Y, Ogino H, Ihara E, Nakamura K, Nishihara Y, Nishioka K, Chinen T, Iwasa T, Aso A, Goto A, Haraguchi K, Akiho H, Harada N, Ogawa Y. Mucosal Profiles of Immune Molecules Related to T Helper and Regulatory T Cells Predict Future Relapse in Patients With Quiescent Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1019-27. [PMID: 30668727 DOI: 10.1093/ibd/izy395] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
567 Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E800. [PMID: 32183476 DOI: 10.3390/jcm9030800] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
568 Walter Sobrado C, Sousa Freitas Queiroz N, Almeida Perez C. Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease. Biological Therapy for Inflammatory Bowel Disease 2020. [DOI: 10.5772/intechopen.90204] [Reference Citation Analysis]
569 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
570 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol 2020;55:579-87. [PMID: 32130521 DOI: 10.1007/s00535-020-01678-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
571 de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. Inflamm Bowel Dis 2019;25:937-44. [PMID: 30329045 DOI: 10.1093/ibd/izy325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
572 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
573 Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-biroulet L. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease 2020;52:281-8. [DOI: 10.1016/j.dld.2019.09.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
574 Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-biroulet L, Nachury M, Boschetti G, Flourié B, Danion P, Savoye G, brazier F, Loreau J, Beaugerie L, Sokol H, Nion-larmurier I, Bourrier A, Landman C, Lefèvre J, Chafai N, Bouta N, Funakoshi N. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2020;18:620-627.e1. [DOI: 10.1016/j.cgh.2019.05.060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
575 Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastro 2020;18:15-32. [DOI: 10.1007/s11938-019-00259-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
576 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 53.5] [Reference Citation Analysis]
577 Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis 2020;26:1562-71. [PMID: 32105310 DOI: 10.1093/ibd/izaa025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
578 Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. Clin Gastroenterol Hepatol 2021;19:111-118.e10. [PMID: 32109630 DOI: 10.1016/j.cgh.2020.02.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
579 Sood A, Mahajan R, Singh A, Midha V, Mehta V, Narang V, Singh T, Singh Pannu A. Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. J Crohns Colitis. 2019;13:1311-1317. [PMID: 30873549 DOI: 10.1093/ecco-jcc/jjz060] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 38.5] [Reference Citation Analysis]
580 Pisani LF, Moriggi M, Gelfi C, Vecchi M, Pastorelli L. Proteomic insights on the metabolism in inflammatory bowel disease. World J Gastroenterol 2020; 26(7): 696-705 [PMID: 32116417 DOI: 10.3748/wjg.v26.i7.696] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
581 Nene S, Gonczi L, Kurti Z, Morin I, Chavez K, Verdon C, Reinglas J, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL. Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World J Gastroenterol 2020; 26(7): 759-769 [PMID: 32116423 DOI: 10.3748/wjg.v26.i7.759] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
582 Lefevre PLC, Shackelton LM, Vande Casteele N. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs 2019;33:453-68. [PMID: 31301024 DOI: 10.1007/s40259-019-00366-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
583 Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
584 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
585 Lindholm CR, Siegel CA. Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials? Curr Pharm Des 2019;25:64-8. [PMID: 30864506 DOI: 10.2174/1381612825666190312113935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
586 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
587 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020;51:689-698. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
588 Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
589 Agrawal M, Ungaro RC, Colombel JF. New Blood Marker of Endoscopic Disease Activity-A Step Forward in Treating Crohn's Disease to Target? Gastroenterology 2020;158:463-5. [PMID: 31866244 DOI: 10.1053/j.gastro.2019.12.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
590 D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology 2020;158:515-526.e10. [PMID: 31711925 DOI: 10.1053/j.gastro.2019.10.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 24.5] [Reference Citation Analysis]
591 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
592 Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. J Crohns Colitis. 2019;13:970-975. [PMID: 30698684 DOI: 10.1093/ecco-jcc/jjz029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
593 Jackson BD, De Cruz P. Quality of Care in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:479-89. [PMID: 30169698 DOI: 10.1093/ibd/izy276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
594 Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis 2019;25:427-35. [PMID: 30358848 DOI: 10.1093/ibd/izy319] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
595 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
596 Kim ES, Lee HS, Kim SK, Kim EY, Jang BI, Kim KO, Yang CH, Lee YJ; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol 2020;55:163-8. [PMID: 31984815 DOI: 10.1080/00365521.2020.1714716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
597 Pellino G, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F;  the Italian Society of Colorectal Surgery (SICCR). Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol. 2020;24:105-126. [PMID: 31983044 DOI: 10.1007/s10151-019-02145-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
598 Ma C, Smith MK, Guizzetti L, Panaccione R, Kaplan GG, Novak KL, Lu C, Khanna R, Feagan BG, Singh S, Jairath V, Ananthakrishnan AN. Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). Clin Gastroenterol Hepatol 2020;18:2500-2509.e1. [PMID: 31988046 DOI: 10.1016/j.cgh.2020.01.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
599 Goodsall TM, Noy R, Nguyen TM, Costello SP, Jairath V, Bryant RV. Systematic Review: Patient Perceptions of Monitoring Tools in Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2021;4:e31-41. [PMID: 33855269 DOI: 10.1093/jcag/gwaa001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
600 Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, Ferrante M. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. J Crohns Colitis 2019;13:864-72. [PMID: 30715258 DOI: 10.1093/ecco-jcc/jjz008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 29.0] [Reference Citation Analysis]
601 Selinger C, Carbonell J, Kane J, Omer M, Ford AC. Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission. Frontline Gastroenterol 2021;12:30-8. [PMID: 33493249 DOI: 10.1136/flgastro-2019-101366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
602 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
603 Marinelli C, Zingone F, Inferrera M, Lorenzon G, Rigo A, Facchin S, Caccaro R, D'Incà R, Savarino EV. Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. J Dig Dis 2020;21:81-7. [PMID: 31859432 DOI: 10.1111/1751-2980.12837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
604 Yamamoto T, Carvello M, Lightner AL, Spinelli A, Kotze PG. Up-to-date surgery for ulcerative colitis in the era of biologics. Expert Opin Biol Ther. 2020;20:391-398. [PMID: 31948294 DOI: 10.1080/14712598.2020.1718098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
605 Xiang L, Ding X, Li Q, Wu X, Dai M, Long C, He Z, Cui B, Zhang F. Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? MicrobBiotechnol. 2020;13:760-769. [PMID: 31958884 DOI: 10.1111/1751-7915.13536] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
606 Cushing KC, Ananthakrishnan AN. Editorial: histologic normalisation in ulcerative colitis. Authors' reply. Aliment Pharmacol Ther 2020;51:401. [PMID: 31943269 DOI: 10.1111/apt.15621] [Reference Citation Analysis]
607 Hazlewood GS, Pokharel G, Deardon R, Marshall DA, Bombardier C, Tomlinson G, Ma C, Seow CH, Panaccione R, Kaplan GG. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. PLoS One 2020;15:e0227635. [PMID: 31945089 DOI: 10.1371/journal.pone.0227635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
608 Martin A, Nachury M, Peyrin-biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A, Amiot A, Martin A, Gagnière C, Nachury M, Pariente B, Wils P, Peyrin-biroulet L, Zallot C, Bouhnik Y, Treton X, Stefanescu C, Nancey S, Boschetti G, Seksik P, Beaugerie L, Kirchgesner J, Bourrier A, Sokol H, Serrero M, Fumery M, Yzet C, Brazier F, Laharie D, Rivière P, Poullenot F, Buisson A, Gilletta C, Filippi J, Hebuterne X, Allez M, Gornet J, Bouguen G, Siproudhis L, Roblin X, Altwegg R, Pineton de Chambrun G, Dib N, Savoye G, Carbonnel F, Meyer A, Viennot S, Lebaut G; GETAID-Vedo-STOP Study Group. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis 2020;14:896-903. [DOI: 10.1093/ecco-jcc/jjaa005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
609 Ahmad OF, Ayubi H, Clough J, Dart R, Gadhok R, Pannick S, Parkes G, Pavlidis P, Segal J, Sellers P; GLINT Research Network. Quality of care in adult patients with inflammatory bowel disease transferring between healthcare providers: multicentre audit. Frontline Gastroenterol 2020;12:5-10. [DOI: 10.1136/flgastro-2019-101347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
610 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
611 Pinto-Lopes P, Afonso J, Pinto-Lopes R, Rocha C, Lago P, Gonçalves R, Tavares De Sousa H, Macedo G, Camila Dias C, Magro F. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2020;26:1707-1719. [PMID: 31912883 DOI: 10.1093/ibd/izz319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
612 Petitdidier N, Beaugerie L, Carbonnel F, Bourrier A, Treton X, Rajca S, Malamut G, Abitbol V, Allez M, Pelletier AL, Marthey L, Jouet P, Benamouzig R, Amiot X, Bouhnik Y, Amiot A. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Clin Res Hepatol Gastroenterol 2020;44:609-18. [PMID: 31924554 DOI: 10.1016/j.clinre.2019.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Long MD, Rubin DT. Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol 2019;114:713-5. [PMID: 31021831 DOI: 10.14309/ajg.0000000000000235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
614 Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis 2020;26:304-13. [PMID: 31644790 DOI: 10.1093/ibd/izz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
615 Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis 2019;13:541-54. [PMID: 30445584 DOI: 10.1093/ecco-jcc/jjy191] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 31.0] [Reference Citation Analysis]
616 Katz S, Liu Y. Challenges in the Management of Inflammatory Bowel Disease. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_66-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
617 Hoffmann JC. Grundprinzipien der CED-Behandlung. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_14] [Reference Citation Analysis]
618 Ma C, Liu X. Histologic evaluation of disease activity in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00015-3] [Reference Citation Analysis]
619 Rogler G, Biedermann L. Klassifikationen, Indizes, Aktivitätsbeurteilung. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_8] [Reference Citation Analysis]
620 Benson-Pope SJ, Gearry RB. Editorial: better outcomes for Crohn's disease-more than just the drugs? Aliment Pharmacol Ther 2020;51:167-8. [PMID: 31850570 DOI: 10.1111/apt.15543] [Reference Citation Analysis]
621 Chapman TP, Gomes CF, Louis E, Colombel J, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020;5:63-79. [DOI: 10.1016/s2468-1253(19)30186-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
622 Saxena NA, Lee SD. Crohn's Disease. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65949-4] [Reference Citation Analysis]
623 Goran L, State M, Negreanu AM, Negreanu L. Pursuing therapeutic success in Crohn’s disease: A matter of definition, tools and longterm outcomes. Eur J Inflamm 2020;18:205873922096289. [DOI: 10.1177/2058739220962896] [Reference Citation Analysis]
624 Melendez-rosado J, Shen B. Endoscopic scores in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00014-1] [Reference Citation Analysis]
625 Kim S, Park S, Kang Y, Koh H. Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis. European Journal of Gastroenterology & Hepatology 2020;32:17-21. [DOI: 10.1097/meg.0000000000001550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
626 Hirten RP, Lakatos PL, Halfvarson J, Colombel JF. A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2020;18:1336-45. [PMID: 31887444 DOI: 10.1016/j.cgh.2019.12.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
627 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
628 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
629 Kevans D, Kirsch R, Dargavel C, Kabakchiev B, Riddell R, Silverberg MS. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. Inflamm Bowel Dis. 2020;26:1722-1729. [PMID: 31883337 DOI: 10.1093/ibd/izz308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
630 Dulai PS, Jairath V. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? Clin Gastroenterol Hepatol. 2020;18:1300-1308. [PMID: 31887449 DOI: 10.1016/j.cgh.2019.12.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
631 Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther 2020;20:193-203. [PMID: 31859538 DOI: 10.1080/14712598.2020.1707800] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
632 Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637-43. [DOI: 10.1111/apt.15616] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
633 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 572] [Cited by in F6Publishing: 603] [Article Influence: 190.7] [Reference Citation Analysis]
634 Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis 2019;13:725-34. [PMID: 30753371 DOI: 10.1093/ecco-jcc/jjy223] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
635 Gatt K, Schembri J, Katsanos KH, Christodoulou D, Karmiris K, Kopylov U, Pontas C, Koutroubakis IE, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Fragaki M, Balomenos D, Zingboim N, Ben Horin S, Mantzaris GJ, Ellul P. Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. J Crohns Colitis. 2019;13:686-692. [PMID: 30561568 DOI: 10.1093/ecco-jcc/jjy214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
636 Makarchuk PA, Britkina OS, Belousova EA. Budesonide ММХ in the treatment of ulcerative colitis: real world clinical practice. Alʹm klin med 2019;47:505-510. [DOI: 10.18786/2072-0505-2019-47-064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
637 Townsend T, Subramanian S. Editorial: endoscopic inflammation in ileoanal pouches-does it really matter? Aliment Pharmacol Ther 2020;51:170-1. [PMID: 31850575 DOI: 10.1111/apt.15536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
638 Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opin Biol Ther 2020;20:151-61. [PMID: 31815548 DOI: 10.1080/14712598.2020.1702020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
639 Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. Pilot Feasibility Stud 2019;5:145. [PMID: 31890258 DOI: 10.1186/s40814-019-0538-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
640 Hallé E, Azahaf M, Duveau N, Lambin T, Nachury M, Branche J, Gérard R, Lauriot Dit Prevost C, Wils P, Desreumaux P, Ernst O, Pariente B. Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease. Dig Dis Sci 2020;65:2664-74. [DOI: 10.1007/s10620-019-05979-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
641 Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1309-1323.e4. [PMID: 31812657 DOI: 10.1016/j.cgh.2019.11.052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
642 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020; 18: 2518-2525. e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
643 Gallego JC, de Juan C, Echarri A, Lopez-de-ullibarri I. Small-Bowel Crohn Disease Treated With Anti–Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes. American Journal of Roentgenology 2019;213:1240-6. [DOI: 10.2214/ajr.19.21186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
644 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 727] [Cited by in F6Publishing: 763] [Article Influence: 242.3] [Reference Citation Analysis]
645 Harris MS, Wichary J, Zadnik M, Reinisch W. Competition for Clinical Trials in Inflammatory Bowel Diseases. Gastroenterology 2019;157:1457-1461.e2. [PMID: 31445038 DOI: 10.1053/j.gastro.2019.08.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
646 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
647 Urlep D, Benedik E, Brecelj J, Orel R. Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study. Eur J Pediatr 2020;179:431-8. [PMID: 31781933 DOI: 10.1007/s00431-019-03520-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
648 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 24.3] [Reference Citation Analysis]
649 Hanžel J, D'Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther 2020;20:399-406. [PMID: 31760827 DOI: 10.1080/14712598.2020.1697227] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
650 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 149] [Cited by in F6Publishing: 163] [Article Influence: 49.7] [Reference Citation Analysis]
651 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 542] [Cited by in F6Publishing: 567] [Article Influence: 180.7] [Reference Citation Analysis]
652 Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7:49-55. [PMID: 32232203 DOI: 10.14744/nci.2018.78800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
653 Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther 2020;51:435-45. [PMID: 31755121 DOI: 10.1111/apt.15577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
654 Yuan Z, Yang L, Zhang X, Ji P, Hua Y, Wei Y. Huang-Lian-Jie-Du Decoction Ameliorates Acute Ulcerative Colitis in Mice via Regulating NF-κB and Nrf2 Signaling Pathways and Enhancing Intestinal Barrier Function. Front Pharmacol 2019;10:1354. [PMID: 31849642 DOI: 10.3389/fphar.2019.01354] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
655 Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:2256-61. [PMID: 31743755 DOI: 10.1016/j.cgh.2019.11.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
656 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
657 Petitdidier N, Tannoury J, de'Angelis N, Gagniere C, Hulin A, Rotkopf H, Mesli F, Brunetti F, Sobhani I, Amiot A. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Dig Liver Dis 2019;51:1652-60. [PMID: 31718934 DOI: 10.1016/j.dld.2019.08.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
658 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-hussuna A, Ellul P, Frei-lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Kenneth Marshall J, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 2020;14:4-22. [DOI: 10.1093/ecco-jcc/jjz180] [Cited by in Crossref: 395] [Cited by in F6Publishing: 415] [Article Influence: 131.7] [Reference Citation Analysis]
659 Weber AT, Shah ND, Sauk J, Limketkai BN. Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence. Curr Treat Options Gastroenterol 2019;17:564-76. [PMID: 31705371 DOI: 10.1007/s11938-019-00248-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
660 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
661 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
662 AlAmeel T, Mosli M. The missing "C": Crohn's, colitis and coping. Saudi J Gastroenterol 2019;25:143-4. [PMID: 31062719 DOI: 10.4103/sjg.SJG_224_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
663 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
664 Martinelli M, Giugliano FP, Strisciuglio C, Urbonas V, Serban DE, Banaszkiewicz A, Assa A, Hojsak I, Lerchova T, Navas-López VM, Romano C, Sladek M, Veres G, Aloi M, Kucinskiene R, Miele E. Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN. Inflamm Bowel Dis 2020;26:1407-14. [PMID: 31689349 DOI: 10.1093/ibd/izz264] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
665 Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. United European Gastroenterol J 2020;8:133-9. [PMID: 32213074 DOI: 10.1177/2050640619887316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
666 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
667 Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Adv Ther 2019;36:3079-95. [PMID: 31562607 DOI: 10.1007/s12325-019-01095-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
668 Pugliese D, Privitera G, Pizzolante F, Gasbarrini A, Guidi L, Armuzzi A. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:280-90. [PMID: 31646853 DOI: 10.23736/S1121-421X.19.02625-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
669 Ankersen DV, Weimers P, Marker D, Bennedsen M, Saboori S, Paridaens K, Burisch J, Munkholm P. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial. World J Gastroenterol 2019; 25(40): 6158-6171 [PMID: 31686770 DOI: 10.3748/wjg.v25.i40.6158] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
670 Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 2019;14:e0223893. [PMID: 31647834 DOI: 10.1371/journal.pone.0223893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
671 Li Y, Schaarschmidt B, Umutlu L, Forsting M, Demircioglu A, Koch AK, Martin O, Herrmann K, Juette H, Tannapfel A, Langhorst J. 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. Eur J Nucl Med Mol Imaging 2020;47:768-77. [DOI: 10.1007/s00259-019-04535-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
672 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
673 Bhattacharya S, Cross RK. Is Endoscopic Remission in Ulcerative Colitis Still Good Enough? Inflamm Bowel Dis 2019;25:1729-30. [PMID: 31412124 DOI: 10.1093/ibd/izz177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
674 Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 20.7] [Reference Citation Analysis]
675 Grover Z, Alex G. Management of inflammatory bowel disease in children: It is time for an individualised approach. J Paediatr Child Health 2020;56:1677-84. [DOI: 10.1111/jpc.14652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
676 Sathananthan D, Rajagopalan A, Van De Ven L, Martin S, Fon J, Costello S, Bryant RV. Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. JGH Open 2020;4:273-9. [PMID: 32280777 DOI: 10.1002/jgh3.12269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
677 Rajagopalan A, Sathananthan D, An YK, Van De Ven L, Martin S, Fon J, Costello SP, Begun J, Bryant RV. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open. 2020;4:267-272. [PMID: 32280776 DOI: 10.1002/jgh3.12268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
678 Chateau T, Le Berre C, Peyrin-Biroulet L. Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases? Clin Gastroenterol Hepatol 2020;18:1030-2. [PMID: 31589974 DOI: 10.1016/j.cgh.2019.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
679 Kayal M, Plietz M, Radcliffe M, Rizvi A, Yzet C, Tixier E, Hirten RP, Cohen B, Sylla P, Khaitov S, Greenstein A, Colombel JF, Dubinsky MC, Ungaro RC. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Aliment Pharmacol Ther 2019;50:1189-94. [PMID: 31579976 DOI: 10.1111/apt.15505] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
680 Adler SN, González Lama Y, Matallana Royo V, Suárez Ferrer C, Schwartz A, Bar-Gil Shitrit A. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity. Endosc Int Open 2019;7:E1253-61. [PMID: 31579707 DOI: 10.1055/a-0982-2786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
681 Camellino D, Dejaco C, Buttgereit F, Matteson EL. Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis? Rheum Dis Clin North Am 2019;45:549-67. [PMID: 31564296 DOI: 10.1016/j.rdc.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
682 Drescher H, Lissoos T, Hajisafari E, Evans ER. Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. The Journal for Nurse Practitioners 2019;15:676-81. [DOI: 10.1016/j.nurpra.2019.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
683 Gonczi L, Bessissow T, Lakatos PL. Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn's Disease. Gastroenterology 2019;157:925-7. [PMID: 31356804 DOI: 10.1053/j.gastro.2019.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
684 Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology 2019;157:1007-1018.e7. [PMID: 31279871 DOI: 10.1053/j.gastro.2019.06.038] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 35.0] [Reference Citation Analysis]
685 Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology 2019;157:1032-1043.e1. [PMID: 31228441 DOI: 10.1053/j.gastro.2019.06.018] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
686 Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology 2019;157:997-1006.e6. [PMID: 31175865 DOI: 10.1053/j.gastro.2019.05.067] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 20.7] [Reference Citation Analysis]
687 Kourkoulis P, Kapizioni C, Michalopoulos G, Andreou N, Papaconstantinou I, Karamanolis G, Gazouli M. Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. European Journal of Gastroenterology & Hepatology 2019;31:1173-83. [DOI: 10.1097/meg.0000000000001490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
688 Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2018;48:839-51. [PMID: 30281832 DOI: 10.1111/apt.14930] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 17.7] [Reference Citation Analysis]
689 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
690 Yang H, Feng R, Fu Q, Xu S, Hao X, Qiu Y, Feng T, Zeng Z, Chen M, Zhang S. Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-α-stimulated gene-6 in inflammatory bowel disease models. Cell Death Dis 2019;10:718. [PMID: 31558705 DOI: 10.1038/s41419-019-1957-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
691 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
692 Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
693 Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J 2019;49:94-100. [PMID: 29962008 DOI: 10.1111/imj.14027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
694 Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis 2019;13:1227-33. [PMID: 30726897 DOI: 10.1093/ecco-jcc/jjz031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
695 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
696 Fournier AP, de Lizarrondo SM, Rateau A, Gerard-brisou A, Waldner MJ, Neurath MF, Vivien D, Docagne F, Gauberti M. Ultrasensitive Molecular Imaging of Mucosal Inflammation Using Leucocyte-Mimicking Particles Targeted to MAdCAM-1.. [DOI: 10.1101/771659] [Reference Citation Analysis]
697 Day A, Wood J, Melton S, Bryant RV. Exclusive enteral nutrition: An optimal care pathway for use in adult patients with active Crohn's disease. JGH Open 2020;4:260-6. [PMID: 32280775 DOI: 10.1002/jgh3.12256] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
698 Yamazaki H, Matsuoka K, Fernandez J, Hibi T, Watanabe M, Hisamatsu T, Fukuhara S. Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). BMJ Open 2019;9:e030134. [PMID: 31501121 DOI: 10.1136/bmjopen-2019-030134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
699 Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
700 Grez C, Ossa JC. ENFERMEDAD INFLAMATORIA INTESTINAL EN PEDIATRÍA, UNA REVISIÓN. Revista Médica Clínica Las Condes 2019;30:372-382. [DOI: 10.1016/j.rmclc.2019.06.009] [Reference Citation Analysis]
701 Røer MJ, Småstuen MC, Røseth AG. Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice. Point of Care 2019;18:85-91. [DOI: 10.1097/poc.0000000000000192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
702 Slimming J. LOGROS Y DESAFÍOS DEL TRATAMIENTO DE LA ENFERMEDAD INFLAMATORIA INTESTINAL EN CHILE. Revista Médica Clínica Las Condes 2019;30:344-348. [DOI: 10.1016/j.rmclc.2019.07.005] [Reference Citation Analysis]
703 Ollech JE, Weisshof R, Rubin DT. PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. Revista Médica Clínica Las Condes 2019;30:339-343. [DOI: 10.1016/j.rmclc.2019.08.001] [Reference Citation Analysis]
704 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
705 Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Journal of Crohn's and Colitis 2020;14:332-41. [DOI: 10.1093/ecco-jcc/jjz151] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
706 Kim AH, Girgis A, De Cruz P, Siegel CA, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study (Preprint).. [DOI: 10.2196/preprints.15946] [Reference Citation Analysis]
707 Nakagawa T, Kobayashi T, Nishikawa K, Yamada F, Asai S, Sameshima Y, Suzuki Y, Watanabe M, Hibi T. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res 2019;17:504-15. [PMID: 31422647 DOI: 10.5217/ir.2019.00030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
708 Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, Ferrante M. Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1142-1151.e10. [PMID: 31446181 DOI: 10.1016/j.cgh.2019.08.030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
709 Le Berre C, Trang-Poisson C, Bourreille A. Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review. World J Gastroenterol 2019; 25(31): 4534-4554 [PMID: 31496630 DOI: 10.3748/wjg.v25.i31.4534] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
710 Marinelli C, Savarino E, Inferrera M, Lorenzon G, Rigo A, Ghisa M, Facchin S, D'Incà R, Zingone F. Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. Gastroenterol Res Pract 2019;2019:5354320. [PMID: 31531015 DOI: 10.1155/2019/5354320] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
711 Yin AL, Hachuel D, Pollak JP, Scherl EJ, Estrin D. Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. J Med Internet Res. 2019;21:e14630. [PMID: 31429410 DOI: 10.2196/14630] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
712 Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review.J Crohns Colitis. 2019;13:374-384. [PMID: 30307487 DOI: 10.1093/ecco-jcc/jjy158] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
713 LeBlanc JF, Wiseman D, Lakatos PL, Bessissow T. Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. World J Gastroenterol 2019; 25(30): 4158-4171 [PMID: 31435170 DOI: 10.3748/wjg.v25.i30.4158] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
714 Klenske E, Atreya R, Hartmann A, Fischer S, Hirschmann S, Zundler S, Iaccuci M, Neurath MF, Rath T. Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. Endosc Int Open 2019;7:E1018-26. [PMID: 31404439 DOI: 10.1055/a-0953-1334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
715 Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohns Colitis 2019;13:424-30. [PMID: 30445625 DOI: 10.1093/ecco-jcc/jjy184] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
716 Aniwan S, Bruining DH, Park SH, Al-Bawardy B, Kane SV, Coelho Prabhu N, Kisiel JB, Raffals LE, Papadakis KA, Pardi DS, Tremaine WJ, Loftus EV Jr. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med 2019;8:E1171. [PMID: 31387259 DOI: 10.3390/jcm8081171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
717 Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A. A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
718 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology 2019;157:320-48. [PMID: 31320109 DOI: 10.1053/j.gastro.2019.03.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
719 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology 2019;17:1680-713. [DOI: 10.1016/j.cgh.2019.02.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
720 Guiotto C, Italia A, Lavagna A, Rigazio C, Cosimato M, Ercole E, Mendolaro M, Rocca R, Daperno M. Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. Digestive and Liver Disease 2019;51:1117-22. [DOI: 10.1016/j.dld.2019.05.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
721 Rahme E, Nedjar H, Afif W. Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. J Can Assoc Gastroenterol 2020;3:257-65. [PMID: 33241178 DOI: 10.1093/jcag/gwz025] [Reference Citation Analysis]
722 Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2019;17:1814-1821.e1. [DOI: 10.1016/j.cgh.2018.10.036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
723 Reinisch W, Gottlieb K, Colombel J, Danese S, Panaccione R, Panes J, Peyrin-biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology 2019;17:1673-1679.e1. [DOI: 10.1016/j.cgh.2018.10.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
724 Samaan MA, Powell N, Irving PM. Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often? Aliment Pharmacol Ther 2019;50:472-3. [PMID: 31359485 DOI: 10.1111/apt.15393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
725 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
726 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
727 Nardone OM, Cannatelli R, Zardo D, Ghosh S, Iacucci M. Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? Therap Adv Gastroenterol 2019;12:1756284819863015. [PMID: 31360224 DOI: 10.1177/1756284819863015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
728 Khanna R, Narula N, Feagan BG. The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1619-23. [PMID: 29846593 DOI: 10.1093/ibd/izy195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
729 Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J 2019;7:1171-82. [PMID: 31700630 DOI: 10.1177/2050640619864848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
730 Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020;18:14-23. [PMID: 31301452 DOI: 10.1016/j.cgh.2019.07.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 15.7] [Reference Citation Analysis]
731 Tavakoli A, Shirzad M, Taghavi A, Fattahi M, Ahmadian-Attari M, Mohammad Taghizadeh L, Rostami Chaijan M, Sedigh Rahimabadi M, Akrami R, Pasalar M. Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Galen Med J 2019;8:e1307. [PMID: 34466491 DOI: 10.31661/gmj.v8i0.1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
732 Bazarganipour S, Hausmann J, Oertel S, El-Hindi K, Brachtendorf S, Blumenstein I, Kubesch A, Sprinzl K, Birod K, Hahnefeld L, Trautmann S, Thomas D, Herrmann E, Geisslinger G, Schiffmann S, Grösch S. The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. J Clin Med 2019;8:E971. [PMID: 31277430 DOI: 10.3390/jcm8070971] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
733 Deepak P, Axelrad JE, Ananthakrishnan AN. The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointestinal Endoscopy Clinics of North America 2019;29:447-70. [DOI: 10.1016/j.giec.2019.02.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
734 Armstrong P, Hall BJ. The current and potential future role of capsule technology in Crohn's disease. The Lancet Gastroenterology & Hepatology 2019;4:493-4. [DOI: 10.1016/s2468-1253(19)30144-x] [Reference Citation Analysis]
735 Fluxa D, Abreu MT. Therapeutic targets in inflammatory bowel disease. Revista Médica Clínica Las Condes 2019;30:315-322. [DOI: 10.1016/j.rmclc.2019.06.008] [Reference Citation Analysis]
736 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
737 Bitar H. More pictures: better clarity or more artifact. Gastrointestinal Endoscopy 2019;90:168. [DOI: 10.1016/j.gie.2019.01.024] [Reference Citation Analysis]
738 Ha JE, Jang EJ, Im SG, Sohn HS. Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014). Korean J Clin Pharm 2019;29:79-88. [DOI: 10.24304/kjcp.2019.29.2.79] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
739 Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon JW, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease. J Gastroenterol Hepatol 2019;34:2118-25. [PMID: 31039275 DOI: 10.1111/jgh.14696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
740 Politis DS, Katsanos KH, Papamichael K, Saridi M, Albani E, Christodoulou DK. Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores? World J Gastrointest Endosc 2019; 11(6): 424-426 [PMID: 31236195 DOI: 10.4253/wjge.v11.i6.424] [Reference Citation Analysis]
741 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
742 Bryant RV, Costello SP. Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Aliment Pharmacol Ther 2019;50:103-4. [PMID: 31184388 DOI: 10.1111/apt.15284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
743 Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
744 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
745 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40-53. [PMID: 31165509 DOI: 10.1111/apt.15294] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
746 D’arcangelo G, Oliva S, Dilillo A, Viola F, Civitelli F, Isoldi S, Cucchiara S, Aloi M. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2019;68:841-6. [DOI: 10.1097/mpg.0000000000002262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
747 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 19.3] [Reference Citation Analysis]
748 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
749 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [